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Regulation of human salt and fluid homeostasis is of basic biological importance. Kidney 
functions allow surviving under a wide variety of conditions with high or low salt diets and with 
high or low intake of fluids, even over long periods of times. Ion and water excretion is 
regulated by a complex network which responds to the internal and environmental conditions. 
The response to hypovolemia could lead to retaining sodium and excreting more potassium, 
while in hyperkalemia the excretion of potassium may not be accompanied with differences in 
the sodium chloride excretion. This controlling network consists mainly of the with-no-lysine 
kinases (WNKs) and the mineralocorticoid receptor (aldosterone receptor, MR) and their 
downstream effectors. Genetic polymorphisms in ion transporters were shown to affect the ion-
balance excretion with and without diuretic drugs, but no comprehensive study has been 
performed to study the effects of the polymorphisms in the regulating genes. 
229 Healthy Caucasian volunteers from two clinical studies under different diuretic drugs and 
under sodium chloride restriction days were genotyped for 39 polymorphisms in 11 genes. Two 
genes arose as candidates for further investigation, the aldosterone receptor gene NR3C2 and 
the with-no-lysine 4 kinase gene WNK4. Twelve polymorphisms in the NR3C2 gene were 
selected for further analysis. The association between ion excretion and the minor A-allele of 
the intron 3 polymorphism (rs3857080) was further investigated in silico and in vitro. The WNK4 
exon regions were sequenced for all healthy volunteers in both clinical studies by massive 
parallel sequencing (Next generation sequencing).  
The intron 3 polymorphism (rs3857080) in the NR3C2 gene was of high impact mostly on 
potassium excretion in both clinical studies. The effect of this polymorphism was seen after the 
sodium chloride restriction days and after the different used diuretics, but it was not seen after 
torsemide which may have antialdosteronergic effect. In silico and in vitro studies showed that 
the intron 3 polymorphism region has a possible binding site for the transcription factor LHX4, 
with higher affinity to bind when the double-strand DNA corresponded to the minor A-allele. 
The same region had an activating effect in reporter gene assays, but there was no consistent 
difference between the two different alleles. The WNK4 gene appeared to be not very 





both clinical studies revealed only five non-synonymous polymorphisms which were confirmed 
by Sanger-sequencing. Two novel polymorphisms in the kinase region of the WNK4 (S239W and 
V358A) were predicted to have deleterious effect on the protein function. 
Concerning the medical impact, carriers of the A-allele of rs3857080 may be more prone to 
hypokalemia from diuretic therapy and its devastating consequences than carriers of the major 
G-allele. The A-allele of the intron 3 polymorphism (rs3857080) may predict a sub-optimal 
outcome from diuretic therapy and heart diseases. More in vitro studies should follow, first to 
confirm the possible impact of the intron 3 polymorphism (rs3857080) in the NR3C2 gene, and 
second to confirm the consistency of the bioinformatics predictions on the WNK4 
polymorphisms with the real effects. 
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1.1 The role of the kidneys 
The two kidneys in the human body are responsible for a number of major functions. These 
functions include activating or producing hormones, filtering and removing a number of toxins 
from the blood and keeping the salt and water homeostasis in the body. The kidneys can 
activate vitamin D and produce erythropoietin. Removing some toxins involves metabolism 
within the kidneys and excretion, particularly of the hydrophilic metabolites in the urine. 
Contribution to homeostasis partially means regulation of the acid-base balance and the 
electrolyte balance, which could lead directly to the regulation of the blood pressure. The major 
functional unit in the kidneys is the nephron which is responsible for the filtering, secreting and 
reabsorbing functions (Figure 1). Each kidney has approximately one million nephrons. Each 
nephron is an independent unit, until it merges with one or more nephrons with the collecting 
duct (Boron and Boulpaep, 2012). 
 
  Figure 1: The nephron and its subdivisions 






1.1.1 The nephron: Anatomy and function 
Each nephron is divided into several functional parts (Figure 1). These functional parts differ by 
their role which is directly related to the type of transporters, regulators and receptors that 
could be found in this exact part. The nephron starts with the Bowman’s capsule followed by 
the proximal tubule, the loop of Henle (descending and ascending), the distal convoluted tubule 
(which is further divided to part 1 proximal and 2 distal depending on the sensitivity to the 
aldosterone), the collecting tubule and finally the collecting duct. 
In the glomerular capillary loops, ultrafiltration of plasma fluid into the Bowman’s capsule yields 
the primary urine. In the proximal tubules, approximately 70% of the ultrafiltrate is retrieved by 
isosmotic reabsorption of sodium and chloride and water. In the thick portion of the ascending 
limb of Henle’s loop, sodium and chloride are absorbed unaccompanied with water. In the distal 
tubule, sodium and chloride and water are again jointly reabsorbed. At the end of the nephron, 
the process involves an aldosterone-controlled exchange of sodium against potassium or proton 
[H+]. In the collecting tubule, vasopressin increases the epithelial permeability for water, which 
is drawn into the hyperosmolar environment of the renal medulla and thus retained in the body. 
As a result, concentrated urine enters the renal pelvis. 
 
1.2 Biomedical impact of renal salt and water regulation 
Regulation of a single cell and total organism salt and fluid contents is of basic biological 
importance for any higher organism living outside the water. In humans, kidney functions allow 
to survive under a wide variety of conditions with high or low salt diets and with high or limited 
intake of fluids even over long periods of times. 
There is strong evidence that reduced renal salt elimination may result in hypertension. For 
instance, treatment with glucocorticoids or aldosterone analogues increased blood pressure 
(both increase renal salt retention). There is also strong evidence that at least a subset of the 
human population, those who are salt sensitive (e.g. Elderly, African Americans, and obese 
individuals) may have a greater decrease in blood pressure with reduced salt intake due to a 
lower activation of the rennin-angiotensin-aldosterone system (Frisoli et al., 2012). Mechanisms 





1) inhibiting the sodium pump by high sodium and low potassium concentrations in the 
extracellular fluid leading to increased intracellular sodium, and driving calcium into cells, which 
induces smooth muscle contraction and thus increases peripheral vascular resistance (Adrogue 
and Madias, 2007). 2) Turning the excess sodium to an osmotically inactive form by storing it in 
the subcutaneous lymphatic system then acts as a fluid-buffering system to reduce the blood 
pressure increase during excessive salt intake (Machnik et al., 2009). And 3) it is suggested that 
many individual genes influence the body’s handling of sodium to varying degrees 
(O'Shaughnessy and Karet, 2006). 
 
1.3 Major renal salt transporters and their regulatory networks 
A multi-gene network is essential to the regulation of renal sodium and potassium excretion. 
Alteration in the signaling through the network can yield in different handling of the renal 
sodium and potassium with different consequences including different types of hypertension. 
The network includes kinases like the with-no-lysine kinases (WNKs), the Ste20-related proline–
alanine-rich kinase (SPAK), oxidative stress response kinase (OSR1), and receptors like the 
mineralocorticoids receptor (MR, aldosterone receptor), and their effectors like the thiazide 
sensitive sodium chloride co-transporter (NCC), sodium-potassium-di-chloride co-transporters 2 
(NKCC2), epithelial sodium channel  (ENaC), and renal outer medullary potassium channel  
(ROMK). Some evidence indicates that the kinase network normally functions as a molecular 
switch to change the mineralocorticoid receptor response in the kidney to either conserve 
sodium or excrete potassium, depending on whether aldosterone is induced by a change in 
dietary sodium or potassium (Castaneda-Bueno et al., 2012; Hoorn et al., 2011; Seva Pessoa et 
al., 2013; Welling et al., 2010). 
The expression of this regulating system can differ within the different functional parts of the 






Figure 2: Expression of the WNKs kinase system in the nephron 
 
 
1.4 The genetic effects 
Genetic disorders usually involve the inheritance of a specific mutated disease-causing gene 
“Monogenetic disorders”, such as sickle cell anemia. The mutated gene is passed down through 
a family, and each generation of children can inherit the gene that causes the disease. Rarely, 
one of these monogenic diseases can occur spontaneously in a child when parents do not have 
the disease gene, or there is no history of the disease in the family. This can result from a new 
mutation occurring in the egg or sperm that arise in that child. 
Most genetic disorders are however “multifactorial inheritance disorders”, meaning that they 
are caused by a combination of inherited mutations in multiple genes often acting together with 
environmental factors. Examples of such diseases include many commonly-occurring diseases, 
such as diabetes and hypertension, which are present in many people in different populations 
around the world.  
Research on the human genome has shown that although many commonly occurring diseases 
are usually caused by inheritance of mutations in multiple genes at once, such common diseases 





that cause or strongly predispose a person to these diseases run in a family, and can significantly 
increase each family member’s risk of developing the disease. One example is hypertension, 
where inheritance of a mutated sodium-chloride co-transporter gene SLC12A3 leads to the risk 
of developing Gordon’s syndrome. 
1.4.1 Rare monogenetic disorders 
Genetic variations in the genes coding networks mentioned above (Figure 2) seem to have a big 
role in salt homeostasis. A number of loss-of-function mutations may lead to hypotension like 
the loss of function mutations in NKCC2 causing Bartter’s syndrome, loss of function mutations 
in NCC causing Gitelman’s disease, loss of function mutations in ENaC that can cause the 
hypotension of pseudohypoaldosteronism type 1 (PHA1). While gain of function mutations may 
result in hypertension just like Gordon’s syndrome and Liddle’s syndrome (Table 1, Figure 3) 
(Lang et al., 2005). 
 





Bartter’s syndrome Loss of function NKCC2 
Hypotension 
Hypokalemic metabolic alkalosis 
Gitelman’s syndrome Loss of function NCC 
Hypotension 
Hypokalemic metabolic alkalosis 
Pseudohypoaldosteronism Type 1 
(PHA I) 
Loss of function ENaC 
Hypotension 
Hyperkalemia 
Pseudohypoaldosteronism Type 2 
(PHA II, Gordon’s syndrome) 
(Gain) of function * NCC 
Hypertension 
Hyperkalemia 
Liddle’s syndrome Gain of function ENaC 
Hypertension 
Hypokalemia 
* There is no known gain of function mutation in the gene coding NCC (SLC12A3), but the regulators like WNK1 and WNK4. 
Deletion in large part of WNK1 gene can lead to excess in L-WNK1 protein and that may lead to pseudohypoaldosteronism type 2 







Figure 3: Transporters in the different nephron parts, diuretics and their targets 
Diuretics are in the red boxes according to their targets (Marked in bold). 
 
 
1.4.2 Common genetic variation (Frequent multi-allelic variation) 
Many studies tried to elucidate the association between measurable renal-function related 
phenotypes and a number of frequent genetic variations. Table 2 summarizes some results 
about the association of some phenotypes with frequent genetic polymorphisms in the renal 










Table 2: Frequent genetic variations in major renal salt transporters and their regulatory proteins 
Protein Gene Variation Medical impact of polymorphism Citation 
NKCC2 SLC12A1 rs2291340 
Associated with HTN in Japanese 
females even after Bonferroni 
correction 
(Iwai et al., 
2004) 
NCC SLC12A3 rs13306673 











ROMK KCNJ1 rs2846679 Strong association with mean 24-h SBP 
(Tobin et al., 
2008) 
ClC-Ka CLCNKa rs1010069 
Significantly associated with BP change 
after Na-load in Hypertension patients 
(Barlassina et al., 
2007) 
NEDD4L NEDD4L rs4149601 
Influences the efficacy of β-blocker and 
diuretic-based antihypertensive 
treatment both in terms of blood 
pressure reduction and cardiovascular 
disease protection 
(Svensson-
Farbom et al., 
2011) 
WNK1 WNK1 rs765250 
Significant association with mean 24-
hour and nighttime SBP and with mean 
nighttime DBP 
(Tobin et al., 
2005) 
WNK4 WNK4 agactttaga(G/A)gtggggtcta 
The frequency of the rare allele differed 
significantly between hypertensive and 
normotensive whites 




NR3C2 rs11099681, rs4835493 
These two SNPs were significantly 
associated with SBP 
(Montasser et 
al., 2011) 
HTN: Hypertension, SBP: Systolic blood pressure, DBP: Diastolic blood pressure. 
 
 
1.4.3 Ethnic differences 
A major topic in genomic variation of renal salt transport is related to ethnic differences. Such 
differences may have appeared through different environmental conditions during evolution 





these ethnic differences are relevant concerning disease susceptibility, drug effects and side 
effects like the difference in response to furosemide between black and white populations due 
to the difference in active NKCC2 co-transporters (Chun et al., 2008). For reasons of feasibility 
we did not study ethnic differences in this work (The volunteers of our two clinical studies had 
German family origins). 
 
1.5 Aldosterone receptor 
The aldosterone receptor, also called the mineralocorticoid receptor (MR), is a nuclear hormone 
receptor which plays an important role in sodium reabsorption and potassium excretion. The 
major role of the aldosterone receptor in keeping the sodium homeostasis was identified in MR-
knockout mice model by the massive salt-waste phenotype (Berger et al., 1998). The functional 
role of the MR is partially mediated by transcriptional regulation of ENaC (Lifton et al., 2001; 
Mick et al., 2001; Pearce and Kleyman, 2007). Modulation of the renal outer medullary 
potassium channel (ROMK) mediated by the aldosterone receptor has also been suggested but 
less investigated (Arroyo et al., 2011; Fodstad et al., 2009). 
1.5.1 Gene and protein structure 
The assignment of the gene coding for the aldosterone receptor has been done almost 25 years 
ago (Morrison et al., 1990). The gene coding the aldosterone receptor is called NR3C2 (nuclear 
receptor subfamily 3, group C, member 2) and is located on chromosome 4 (q31.1 region). The 
gene spans almost 370 kb and is composed of nine exons. The first exon is untranslated, while 
the eight following exons are encoding the aldosterone receptor protein which consists of 
984 amino acids. 
The protein has three main regions, the N-terminal domain NTD (encoded by exon 2), the DNA-
binding domain DBD (exon 3 and exon 4 are encoding the two zinc fingers in this domain) and 
finally the C-terminal ligand-binding domain LBD (encoded by the last five exons) (Viengchareun 
et al., 2007). The aldosterone receptor is located in the cytoplasm under the free-ligand-binding 
status. It translocates to the nucleus after the activation by aldosterone binding (Binart et al., 
1991; Lombes et al., 1994). The aldosterone receptor could be phosphorylated in minutes also 





the slow genomic effects of MR and the fast non-genomic effects (Funder, 2005), but the fast 
non-genomic effects are still controversial. 
1.5.2 Aldosterone paradox 
The renal regulation of sodium and potassium balance have been shown to be independent 
(Castaneda-Bueno et al., 2012). This observation may lead to a better understanding of the 
different response from the aldosterone receptor to either hypovolemia or hyperkalemia. The 
major response to hypovolemia would be more sodium reabsorption without affecting 
potassium excretion, while in hyperkalemia, the sodium chloride is not affected but potassium 
excretion is elevated in the distal nephron. These two different responses term what is now 
known as “aldosterone paradox” (Halperin et al., 2006). The key point in these two different 
responses is believed to be the interaction between effects of the aldosterone and 
Angiotensin II (Figure 4) (Arroyo et al., 2011; Hoorn et al., 2011; Seva Pessoa et al., 2013). 
 
Figure 4: Aldosterone paradox and WNK4 conundrum 
In hypovolemia (Part A), Angiotensin II leads to more aldosterone production and both will recruit WNKs-SPAK/OSR1 or SGK1 
pathways to give the end effects of activating ENaC and NCC while blocking ROMK through WNK4. In hyperkalemia (Part B), 
WNK4 is blocking NCC in the DCT 1 part of the nephron leading to more sodium delivered to the last parts of the nephron in the 






1.5.3 Aldosterone receptor polymorphisms 
A number of polymorphisms in the aldosterone receptor gene, NR3C2, have been implicated 
with in vivo phenotypes. Table 3 shows the twelve polymorphisms which had been associated 
with specific biological or medical phenotypes. The Ile180Val amino acid substitution (rs5522) 
has been especially implicated with neuropsychiatric phenotypes (DeRijk et al., 2006; Kortmann 
et al., 2013; Rovaris et al., 2013) however, diuretic drug effects have been poorly investigated in 
relation to these polymorphisms. 
 



















































































































(Song et al., 2011) Blood pressure 
  
↑ 




(Martinez et al., 2009) Blood pressure  ↓           





      ↑   ↑   
(Tobin et al., 2008) 
Night time systolic blood 
pressure 
    ↓        
(Montasser et al., 2011) 
Blood pressure in 
physically active subjects 
     ↓  ↓     
(van Leeuwen et al., 2011) NR3C2 expression ↑ -           
(Derijk et al., 2008) 
Cortisol blood 
concentrations with 
rs2070951; heart rate with 
Ile180Val 
↓ ↑           
(Klok et al., 2011) 
Morning cortisol in 
depression 
↑ -           
(Nossent et al., 2011) Myocardial infarction            ↑ 
(Pan et al., 2011) Intelligence quotient    ↑         






1.6 With-no-Lysine kinases (WNKs) 
Protein kinases are important mediators in many cell processes. After their activation, they 
regulate downstream proteins by phosphorylation. Protein kinases have usually a conserved 
core (Hanks et al., 1988), they have usually a conserved lysine located in the subdomain II 
(Knighton et al., 1991). A novel class of protein kinases was discovered fourteen years ago 
where the conserved lysine was surprisingly located in the Subdomain I rather than 
subdomain II (Verissimo and Jordan, 2001; Xu et al., 2000). These kinases were termed as the 
With-No-Lysine [K] kinases and they belong to the serine/threonine kinases. Four genes are 
encoding the human WNKs, located in chromosomes 12, 9, X and 17 for the WNK1-4 
respectively. WNKs are widely expressed, with high levels of WNK1 in the testis, heart and 
kidneys (O'Reilly et al., 2003). WNK2 is not expressed in the kidneys but in the heart, brain and 
colon (Verissimo and Jordan, 2001). WNK3 is expressed with low levels in brain, lung, kidneys, 
liver and pancreas and some fetal tissues (Holden et al., 2004; Verissimo and Jordan, 2001). 
WNK4 is found in tissues with secretory epithelia like kidneys, colon and blood brain barrier 
(Kahle et al., 2004; Verissimo and Jordan, 2001). There is also a truncated isoform of WNK1 
lacking most of the kinase domain which is expressed only in the kidneys and called kidney-
specific WNK1 (ks-WNK1) (Xu et al., 2002).  
WNKs contain multiple domains for protein-protein interactions other than the Kinase domain. 
For that, many studies have divided the WNKs’ pathways into two categories: Catalytic way 
when it is contributing phosphorylation by the kinase domain (Figure 5 A), and Non-catalytic 
way as the non-kinase dependent pathway (Figure 5 B) (Flatman, 2007; Hoorn et al., 2011; 







  Figure 5: WNKs’ cascade under basal conditions 
DCT: Distal Convoluted Tubule.  ks-WNK: Kidney Specific WNK1, L-WNK: Full-length transcript of WNK1. WNKs, SGK1, SPAK, 
OSR1: Kinases. NEDD4L: Phosphatase. NKCCs, NCC, ENaC, ROMK: transporters. MR: mineralocorticoid receptor (Aldosterone 
receptor). Figure 2 is described in details under Aldosterone paradox [1.5.2], the With-no-lysine kinases [1.6] and the WNK4 
conundrum [1.6.1] paragraphs. 
 
For the catalytic way and in cultured cells, the hyperosmolar conditions as well as low chloride 
conditions were the triggers to activate WNKs (WNK1 and 3) (Richardson and Alessi, 2008) 
which in turn phosphorylate SPAK/OSR1 kinases which also phosphorylate and activate NKCC2 
and NCC (Flatman, 2007; Hoorn et al., 2011). The exact role of WNK4 in this catalytic way has 
not yet exactly clarified as the wt-WNK4 inhibits the NCC (see [1.6.1]). 
In the non-catalytic way, potassium concentration in the outer media seems to have the big role 
to activate either L-WNK1 (full length isoform of WNK1) or ks-WNK1. Ks-WNK1 inhibits the 
activity of L-WNK1 which in turn inhibits the activity of WNK4. WNK3 and WNK4 inhibit each 
other’s effects (Hoorn et al., 2011). 
The regulation mechanisms of the ion transporters by the WNKs under kinase-dependent or 
independent ways usually include the effects on the cell surface expression or the activity of the 





Analysis of the physiological and pathophysiological roles of the WNKs is still in the very 
beginning step, but hypertension seems to be an obvious therapeutic target for WNK-specific 
inhibitors (more specifically WNK1 and WNK3). While a better understanding of WNKs action in 
vivo is required (especially WNK4), the development of specific inhibitors of the WNKs is already 
under construction as structural analysis suggested that specific WNK1 inhibitors could be 
designed in principle (McCormick and Ellison, 2011). 
1.6.1 The WNK4 conundrum 
The term conundrum was introduced to refer to the still incompletely understood functions of 
WNK4 (Arroyo et al., 2011). This kinase could have three major (known or expected) functional 
states under different conditions to activate or inhibit the same ion transporter or channel 
(Figure 4, Figure 5). The first state is under the basal conditions when WNK4 has inhibitory 
effects on NCC, ENaC and ROMK (wt-WNK4). The second state is under hypovolemia conditions 
when the inhibition of NCC and ENaC is lost but not the inhibition of ROMK (PHA II-type-WNK4). 
The third state is observed under hyperkalemia when the inhibition of NCC stays in the non-
aldosterone-sensitive parts of the nephron (DCT1) while the inhibition of ENaC and ROMK is 
lost, most likely because of the phosphorylation of WNK4 at position S1169 by SGK1 which is 
induced be the aldosterone. The effects on NCC in the DCT2 part of the nephron in the third 
state, which is aldosterone sensitive, needs to be clarified, but the net effect on NCC would be 
expected to be as with low activity due to the high expressed amount of NCC in DCT1 compared 
with DCT2 (Arroyo et al., 2011). In one study (Lalioti et al., 2006), two different mice models 
were generated, each of them has four copies of the WNK4. The first model has four wt-WNK4 
while the second model has two wt-WNK4 and two PHA II-type-WNK4. The mice from the first 
model developed symptoms like Gitelman’s syndrome while the second mice model developed 
PHA II like symptoms. These results suggest that the PHA II-type-WNK4 is an autosomal 






1.7 Diuretic drugs 
Diuretic drugs control salt, water excretion and blood pressure and are the most important 
drugs in hypertension and heart failure (Chobanian et al., 2003; Mancia et al., 2013; McMurray 
et al., 2012; Yancy et al., 2013). 
Some of the diuretics were used successfully to treat diseases from genetic origins like 
pseudohypoaldosteronism Type 2 (Gordon’s syndrome) like thiazides (Mayan et al., 2002). 
Diuretic drugs are divided into many groups according to their physiological actions. They 
include carbonic anhydrase inhibitors, osmotic diuretics, loop diuretics, thiazides and 
potassium-sparing diuretics. 
Carbonic anhydrase inhibitors (e.g. acetazolamide) have a weak diuresis effects and are rarely 
used other than an eye drops against glaucoma. Osmotic diuretics (e.g. mannitol) are used to 
treat cerebral edema and raised intra-ocular pressure. Loop diuretics (e.g. furosemide) are the 
most effective drugs among the diuretics and they are acting by blocking the NKCC2 activity in 
the thick ascending limb of Henle (TAL). Loop diuretics are used as antihypertensive treatment 
to control blood pressure in patients with resistant hypertension, or in patients with impaired 
renal function or heart failure. Loop diuretics can be used intravenously in pulmonary edema 
due to left ventricular failure. Thiazides (e.g. hydrochlorothiazide) are the moderate diuretics 
and their effect is coming from blocking the NCC in the distal convoluted tubule (DCT). The 
thiazides are used widely in the management of hypertension. Potassium-sparing diuretics can 
be divided into two groups: The ENaC inhibitors (e.g. triamterene) and the aldosterone 
antagonists (e.g. spironolactone). They are also weak diuretics and used usually in combination 
with the thiazide diuretic to antagonize the potassium sparing effects (Committee, 2013). Table 










Table 4: Diuretics according to nephron parts 
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1.8 Aim of the work 
Rare genetic variants and frequent polymorphisms in the sodium-potassium-dichloride co-
transporters (NKCC2), the sodium-chloride co-transporters (NCC) and the epithelial sodium 
channels (ENaC) have been reported to affect electrolyte excretion when diuretics are applied 
(Vormfelde et al., 2007). Little has been studied thus far regarding the functional effects of the 
regulatory pathways regulating short and long term activity of the renal ion transporters. This 
project should contribute to a better understanding of variation in renal functions concerning 
electrolyte excretion.  
Major focus of this study is the impact of genomic variations in the renal salt transporters and 
their regulatory pathways on the effects and side effects of diuretic drugs (Figure 6). More 
concretely, we wanted to identify inherited genetic polymorphisms which explain a significant 
part of variation in renal elimination of sodium, chloride, potassium and urine volume. We 
wanted to do this using the so-called candidate-gene approach focusing on genes coding for the 
ion transporters and the proteins regulating the activity of the ion transporters. 
 
Figure 6: Aim of the work: Genetic polymorphisms in genes regulating renal ion excretion and diuretic drug effects 
 
Medically, this project might contribute to a better understanding of both rare monogenetic 
renal disorders on one side and multifactorial inheritance disorders such as hypertension, 
diabetes and osteoporosis on the other side. 




2 Materials and methods 
2.1 Materials 
2.1.1 Reagents, kits, media and enzymes 
Reagents, kits, media and enzymes Distributer / Manufacturer* 
[α-32P]-dCTP (for EMSA) Hartmann Analytic GmbH, Braunschweig 
1 kb Size standard ladder for agarose gel ABgene, Fermentas, St. Leon-Rot 
100 bp Size standard ladder for agarose gel ABgene, Fermentas, St. Leon-Rot 
40% (w/v) Acrylamide:Bis-acrylamide / Mix 
37.5:1 
Biomol, Hamburg 
4326322E (RT-assay, TBP gene) Applied Biosystems, Darmstadt 
Agar (for bacteriology) AppliChem, Darmstadt 
Agarose Ultra Pure (for sequencing) Invitrogen, Karlsruhe 
All oligonucleotides for PCR or EMSA Eurofins MWG synthesis GmbH, Ebersberg 
Ammonium persulfate ≥ 98% Sigma-Aldrich, Deisenhofen 
Ampicillin min. 99% AppliChem, Darmstadt 
AmpliSeqTM Library Kit 2.0 (for target 
enrichment) 
Life technologies, Darmstadt 
Anti-BARX1 antibody (rabbit) Sigma-Aldrich, St. Louis, USA 
Anti-LHX4 antibody (rabbit) Sigma-Aldrich, St. Louis, USA 
Aquasafe 500 Plus (safety scintillator 
solution) 
Zinser Analytic, Berkshire 
BglII Fermentas, St. Leon-Roth 
Bicinchoninic Acid Solution Sigma-Aldrich, Deisenhofen 
BigDye® v1.1 Sequencing Kit (fluorescence 
based Sanger sequencing) 
Applied Biosystems, Darmstadt 
Boric acid 100% Merck, Darmstadt 
Bovine serum albumin (BSA) Sigma-Aldrich, Deisenhofen 




Bromphenol blue Na-Salt (for 
electrophoresis) 
Roth, Karlsruhe 
Chloroform ≥ 99.8% J.T. Baker, Phillipsburg, USA 
Compactprep kit (for midi-prep) Qiagen, Hilden 
X-ray developer G150 AGFA, Leverkusen 
Dimethyl sulfoxide (DMSO) AppliChem, Darmstadt 
Dithiothreitol ≥ 99.5% (for Molecular 
biology) 
AppliChem, Darmstadt 
DNeasy Blood & Tissue Kit (For DNA 
extraction) 
Qiagen, Hilden 
dNTP Set ABgene, Hamburg 
Dual-Luciferase® Reporter Assay System Promega, Mannheim 
Dulbecco´s Modified Eagle Medium (DMEM) Gibco/Invitrogen, Karlsruhe 
EcoRI Fermentas, St. Leon-Roth 
EDTA 0.5 M in water solution Sigma-Aldrich, Deisenhofen 
EDTA pure Merck, Darmstadt 
Ethanol 96% Merck, Darmstadt 
Ethanol denatured 99% (Disinfection 
reagent) 
Chemie-Vertrieb Hannover 
Ethidium bromide 1% in H2O (for 
electrophoresis) 
Merck, Darmstadt 
Exonuclease I E.coli (ExoI; 20 u/μl) ABgene, Fermentas, St. Leon-Rot 
EZ1 DNA Blood Kit Qiagen, Hilden 
X-ray fixer G354 AGFA, Leverkusen 
FuGene 6 (Transfection reagent) Roche, Mannheim 
GeneScanLIZ120 (Size standard ladder for 
SNaPshotTM) 
Applied Biosystems, Darmstadt 
Glycerol 85% 
Central pharmacy – University medical center, 
Göttingen 




Helipur® H plus N (Disinfection reagent) Braun, Melsungen 
HEPES 99.5% AppliChem, Darmstadt 
HindIII ABgene, Fermentas, St. Leon-Rot 
HotStarTaq Master Mix Kit (250 units) Qiagen, Hilden 
HS00260769_m1 (RT-assay, WNK4 gene) Applied Biosystems, Darmstadt 
HS01031809_m1 (RT-assay, NR3C2 gene) Applied Biosystems, Darmstadt 
Ion OneTouchTM 200 Template Kit v2 
(Template preparation for the NGS) 
Life technologies, Darmstadt 
Ion library quantitation kit Life technologies, Darmstadt 
Ion PGMTM 200 Sequencing kit Life technologies, Darmstadt 
Isoamyl alcohol 98% Schuchardt, Hohenbrunn 
Isopropanol ≥ 99.9% Merck, Darmstadt 
Klenow-Fragment (For EMSA) ABgene, Fermentas, St. Leon-Rot 
KOD HotStart DNA Polymerase Novagen Merck, Darmstadt 
Ligate-ITTM Rapid Ligation Kit USB europe GmbH, Staufen 
Magnesium chloride ≥ 99% Riedel-De Haën AG, Seelze 
Magnesium sulfate ≥ 99.5% Merck, Darmstadt 
Mini Quick Spin Oligo Columns Roche, Mannheim 
Multiplex PCR Kit Qiagen, Hilden 
Neodisher® A 8 (Cleaning powder) Chem. Fabrik Dr. Weigert, Mühlenhagen 
Normal rabbit antibody IgG (sc-2027) Santa cruz Biotechnology, Heidelberg 
PBS powder (Dulbecco’s 10X for cell culture) AppliChem, Darmstadt 
Penicillin/Streptomycin solution Invitrogen, Karlsruhe 
Poly (deoxyinosinic-deoxycytidylic) (EMSA) Sigma-Aldrich, Deisenhofen 
Poly-d-lysine hydrobromide (For cell 
culture) 
Sigma-Aldrich, Deisenhofen 
Polymer POP6 for sequencer Applied Biosystems, Darmstadt 
Potassium chloride ≥ 99.5% Riedel-De Haën AG, Seelze 
QIAquick Gel Extraction Kit Qiagen, Hilden 




QIAquick PCR Purification Kit Qiagen, Hilden 
qRT-PCR Mastermix 
PrimerDesign Ltd Precision OneStepTM, 
Southampton, United Kingdom 
Random Hexanucleotide Primer dN6 Roche, Mannheim 
RNAse A ~70% AppliChem, Darmstadt 
Sephadex™ G-50 Superfine Amersham Bioscience, Freiburg 
Shrimp Alkaline Phosphatase (1 u/μl) Affymetrix, High Wycombe, United Kingdom 
SnapShotTM Multiplex Kit Applied Biosystems, Darmstadt 
Sodium chloride Merck, Darmstadt 
Super Script II Reverse Transcriptase Invitrogen, Karlsruhe 
Taq DNA Polymerase Qiagen, Hilden 
TEMED ≥ 99% (N,N,N’,N’-
Tetramethylethylenediamine) 
Sigma-Aldrich, Deisenhofen 
Tris 100% (Tris hydroxymethyl 
aminomethane) 
Roth, Karlsruhe 
Trypan blue solution (0.4 %) Sigma-Aldrich, Deisenhofen 
Tryptone AppliChem, Darmstadt 
Xylene cyanol FF (for molecular biology) AppliChem, Darmstadt 
Yeast extract AppliChem, Darmstadt 
* Country was not mentioned for Germany. 
2.1.2 Materials and instruments 
Materials and instruments Distributer / Manufacturer* 
12-Well plate (for Cell culturing) Greiner, Frickenhausen 
3130xl Genetic Analyser (Capillary sequencer) Applied Biosystems, Darmstadt 
384-well plate (FrameStar®) 4titude, Dorking, United Kingdom 
50 ml Centrifuge tube Beckman, München 
96 Millipore MAHV N45 Plate Millipore, Schwalbach 
96er PCR-Plate ABgene, Epsom, United Kingdom 




96-wells Microtiter plate (Cat No 3603) 
Corning® Microtest, North Yorkshire, United 
Kingdom 
Absolute QPCR Seal (Optical Foil for Taqman) Thermo Scientific, Schwerte 
Adhesive PCR Foil Seals ABgene, Epsom, United Kingdom 
Bacteria Incubator-Incudrive Schütt, Göttingen 
Biofuge fresco Heraeus, Hanau 
Biofuge pico Heraeus, Hanau 
BioPhotometer Eppendorf, Hamburg 
BioRobot® EZ1 Qiagen, Hilden 
Centrifuge 5810 R Eppendorf, Hamburg 
Centrifuge JA-20 Rotor Beckman, München 
CO2-Incubator BBD 6220 Heraeus, Hanau 
ComPhor L Mini Gel-chamber Biozym, Hessisch Oldendorf 
Concentrator 5301 Eppendorf; Hamburg 
Culture flask 25 cm² and 75 cm² Sarstedt, Nümbrecht 
Cuvette (UVetten) 50-1000 μl Eppendorf, Hamburg 
Dialyse filter VSWP01300 Millipore, Schwalbach 
Electroporation cuvette 2 mm PeqLab, Erlangen 
Electroporator Gene Pulser II BioRad, Hercules, USA 
Fine weight machine Sartorius, Göttingen 
Flat cap strips, 12er ABgene, Epsom, United Kingdom 
Flat cap strips, 8er ABgene, Epsom, United Kingdom 
Fluor-S™ MultiImager BioRad, Hercules, USA 
gel-drying-system (DrygelSr) 
Hoffer scientific instruments, San Francisco, 
USA 
Glass Pasteur pipette 230 mm WU, Mainz 
GloMax® Luminometer Turner BioSystems, Sunnyvale, USA 
Ion 316TM sequencing chip Life technologies, Darmstadt 
Labofuge 400R Heraeus, Hanau 




Magnetic stirrer Ika, Staufen 
Mastercycler gradient Eppendorf, Hamburg 
Microscope Axiovert 40 CFL Zeiss, Jena 
MS 2 Mini shaker-Vortexer Ika, Staufen 
Nanodrop cuvette Implen, München 
Neubauer-Cell chamber Schütt, Göttingen 
OneTouchTM Life technologies, Darmstadt 
OneTouchTM ES Life technologies, Darmstadt 
Parafilm® Brand, Wertheim 
PerfectBlue Gelsystem Peqlab, Erlangen 
Petri Dish Sarstedt, Nümbrecht 
PGMTM (Personal Genome Machine) 
sequencer 
Life technologies, Darmstadt 
Phosphor Imager Raytest, Sprockhövel 
Pipette Tips (10, 100, 1000 μl) Sarstedt, Nümbrecht 
Plate loader for Sephadex Millipore, Schwalbach 
Plate Retainer for Sequencing Applied Biosystems, Darmstadt 
QiaCube Qiagen, Hilden 
QIAgility (pipetting robot) Qiagen, Hilden 
Quali-Filterpipett tip sterile Kisker, Steinfurt 
Qubit® 2.0 fluorometer Life technologies, Darmstadt 
Scintillation instrument LS1801 Beckman, München 
Shaker for Bacteria K2 260 basic Ika, Staufen 
Sterile Bench-Clean Air type DFL/REC4 KL2A Mahl, Trendelburg 
Sterile Pipette (5, 10, 25 ml) Sarstedt, Nümbrecht 
Sterile Polypropylen-tube 15 ml Greiner, Frickenhausen 
Sterile Polypropylen-tube 50 ml Sarstedt, Nümbrecht 
TaqMan 7900HT Applied Biosystems, Darmstadt 




Thermal Gradient Cycler PTC-200 Peltier MJ Research/BioRad, Hercules, USA 
Thermo-Fast 384-well Plate (PCR-Plates for 
Taqman) 
ABgene Epsom, United Kingdom 
Thermo-Fast 96-well Plate ABgene Epsom, United Kingdom 
Thermomixer 5436 Eppendorf, Hamburg 
Transilluminator TI 2 Biometra, Göttingen 
Vertical-Autoclave KSG 40/60 KSG, Olching 
Vertical-Autoclave: FV Tecnorama, Fernwald 
Water bath GFL 1083 Schütt, Göttingen 
Whatman papers (Filter paper Nr. 2668) Schleicher und Schüll, Dassel 













Software Distributer / Manufacturer* 
3100 Data Collection Software Applied Biosystems , Darmstadt 
Adobe Photoshop® CS4 EXTENDED v11.0.2 Adobe systems, München 
BASreader and AIDA Version 4.15.025 Raytest, Sprockhövel 
BVTech plasmid v5.1 BV Tech 
Clone Manager Suite v6.0 Sci-Ed Software, Cary  NC, USA 
CorelDRAW X3 Corel corporation, Ontario, Canada 
DNA Sequencing Analysis Applied Biosystems , Darmstadt 
DNASTAR® v11.2 DNASTAR, Madison WI, USA 
EndNote X7 Thomson Reuters, Philadelphia PA, USA 
Gene mapper v3.7 software® Applied Biosystems , Darmstadt 
HaploView® v4.2 Broad institute, Cambridge MA, USA 
IBM© SPSS® STATISTICS v20.0 and v21.0 IBM Corp, Ehningen 
Integrative Genomics Viewer (IGV) v3.4.51874 Broad institute, Cambridge MA, USA 
MS Office 2007 / 2013 Microsoft, Unterschleißheim 
Oligo® v6.58 Molecular Biology Insights, Cascade CO, USA 
PHASE® v2.1 
Department of Statistics, University of 
Washington, Seattle, USA 
Quantity One S BioRad, München 
SDS v2.1 Applied Biosystems , Darmstadt 
SigmaPlot for windows v11.0 Systat software, Erkrath 
Staden Package 
Medical research council laboratory of 
molecular Biology, Cambridge, UK 
XFluor4 Software Tecan, Crailsheim 
* Country was not mentioned for Germany. 
 
  





Vector Resistance Distributer / manufacturer* 
pOTB7::LHX4 






pcDNA3.1 Ampicillin Invitrogen, Karlsruhe 
pGL3-promoter Ampicillin Promega, Mannheim 
pCMV Ampicillin Invitrogen, Karlsruhe 
* Country was not mentioned for Germany. 
 
2.1.5 Bacteria 




(One shot TOP10 
Electro-comp. E.coli) 
Escherichia coli Electro-competent 
Invitrogen, 
Karlsruhe 
* Country was not mentioned for Germany. 
 
2.1.6 Cell lines 







* Country was not mentioned for Germany. 
  




2.2 Summary of the clinical studies 
The urinary electrolyte excretion was investigated in two single-dose cross-over studies in 
healthy, male Caucasian volunteers (Vormfelde et al., 2006; Vormfelde et al., 2007). The first 
study was on the loop diuretics bumetanide, furosemide and torsemide. The second study was 
on two doses of hydrochlorothiazide, on triamterene, and on moderate sodium chloride 
restriction. The studies were designed similarly but performed separately. The populations were 
unrelated to each other. Both studies were randomized, single-blind, three-arm, triple-crossover 
studies. Both studies were approved by the ethics committee of the University Medical Center 
Göttingen. All volunteers provided written informed consent before they were included into the 
studies. To avoid hypovolemia, the participants were repetitively encouraged to drink water or 
caffeine-free tea in both studies. 
2.2.1 Study 1 
The first study consisted of three periods separated by at least one week. Each period consisted 
of two days: A run-in day and a drug day. The participants were asked to stick to a salt-restricted 
diet from 48 h prior to drug administration until 24 h after drug intake. Participants were 
advised to restrict salt intake, but no strict salt-controlled diet was administered at the days 
before the study. On the drug days, the participants ingested single oral doses of 2 mg 
bumetanide, 80 mg furosemide and 10 mg torsemide. Blood and urine were collected in 
intervals over 24 h after drug intake. 
112 Caucasian men were recruited. 110 donated blood. 96 participants completed at least one 
study period: 95 the bumetanide period, 93 the furosemide period and 92 the torsemide period. 
The 96 participants were on average 28 years old (mean, range 19–50 years), weighed 78 kg 
(57–93 kg) and were 182 cm tall (170–198 cm). 
2.2.2 Study 2 
The second study also consisted of three periods. These periods were also separated by at least 
one week. Each period consisted of three days: A run-in day, a moderate sodium chloride 
restriction day and a drug day. On the sodium chloride restriction days, a placebo drug was 
taken single-blind. A drug was taken single-blind on the drug days, which were otherwise 
performed identically to the sodium chloride restriction days. Drugs were 25 mg 




hydrochlorothiazide, 100 mg hydrochlorothiazide and 200 mg triamterene. Drugs were given in 
randomized order as single oral doses. Blood and urine were collected in intervals over 24 h. 
The participants were taught and asked to restrict sodium chloride intake on all three day. Diet 
was not controlled on run-in days. Diet was partially controlled on the sodium chloride 
restriction days and drug days. We served low-sodium breakfast, lunch and water (the meals 
were prepared in the special gastronomy kitchen in UMG-klinikum Göttingen).  
For the second study, we recruited 120 Caucasian men, which were unrelated to those of the 
first study. 119 donated blood. 107 participants completed at least one study period: 99 the 25 
mg hydrochlorothiazide period, 99 the 100 mg hydrochlorothiazide period and 101 the 
triamterene period. The 107 participants were on average 28 years old (mean, range 18–49 
years), weighed 78 kg (58–100 kg), and were 183 cm tall (167–201 cm). 
Figure 7 gives an overview of the study design of both clinical studies. 
 
Figure 7: Schematic view of the two clinical studies performed by the institute of clinical pharmacology 




2.2.3 Calculating phenotypes  
To describe the urinary excretion of electrolytes, volume and drugs, we calculated their 
“fraction excreted” (fe). Fe is preferred to describe the urinary excretion when investigating 
diuretic effects (Rudy et al., 1994; Vargo et al., 1995). Fe is calculated as percent denoting 
amounts excreted in the urine in relation to amounts filtered through the glomeruli (fraction 
excreted). Fe is calculated by dividing electrolyte clearance, volume excretion rate or drug 
clearance by the respective creatinine clearance (fe =
𝐶𝑙𝑖𝑜𝑛
𝐶𝑙𝐶𝑟
, Clion is the clearance of the 
respected ion, ClCr is the clearance of the creatinine). 
Secondly, we transformed fe-percentages to gram amounts, which are better comprehensible: 
We multiplied the fe-percentage with the standard glomerular filtration rate of 7.2 l/h 
(=120 ml/min), the respective time interval (h), mean serum concentration (mol/l) and molar 
weight (g/mol). The equation below depicts all what was explained above: 
Amount excreted (g)
= fe × 7.2 (l h⁄ ) × Time interval (h)
× Mean serum concentration of the respected ion (mol l⁄ ) × Molecular weight (g mol)⁄  
 
2.3 Selecting polymorphisms 
2.3.1 General criteria 
General criteria were applied for selecting the polymorphisms. There were several major 
approaches applied when possible. The polymorphism was selected when a functional 
association was generally known or reported in previous studies. Because frequencies of many 
polymorphisms depend on ethnicity, we focused on the Caucasian population (CEU). Tagging 
SNPs which have been defined automatically by the software HaploView 4.2 were selected also. 
The priority was always for the coding SNPs in the exon regions of the genes, then for the non-
synonymous ones considering the minor allele frequency (MAF) to be higher than 1% when 
possible. 
2.3.2 Aldosterone receptor polymorphisms 
The aldosterone receptor gene polymorphisms were selected through a literature search. In 
April 2013, 117 papers were identified after searching PubMed database for [polymorphism and 
("mineralocorticoid" OR "NR3C2" OR "Aldosterone receptor")] with the filters [Human and 




English]. Two contributors (ND, SV) screened these papers by hand and identified twelve 
polymorphisms with significant phenotype associations (Table 3). 
 
2.4 Statistical analysis 
2.4.1 Analyzing all polymorphisms 
For scanning or exploratory purposes, it was considered appropriate to analyze all possible 
predictors in the studied network. The studied network has a number of interacting genes, each 
with different possible roles. It was not enough from this point of view to start the scanning step 
with a fixed statistical model. The use of three statistical models gave broader scope through 
the screening procedure. 
The first statistical model has the diuretic drug excretion as a covariate, and was performed to 
comply with the theory of the relation between the excretion of the diuretic drugs and their 
effects. 
The second statistical model also had the excretion of the diuretic drugs and it had all previously 
known affecting polymorphisms in the studied network and allowed to compare the explained 
variation in the ion excretion that may be resulted from either pharmacogenetic or 
pharmacokinetic factors. The results coming from the second statistical model played also a 
checkpoint role for the previous results of the known affecting polymorphisms when other 
possible factors were included. 
The third statistical model, which did not include any predictors other than the studied 
polymorphism, made it possible to observe the main effect of the genotype groups as a result of 
the polymorphism itself without any other factors. 
The data for the genotype-phenotype association were analyzed by the repetitive analyze of 










Table 5: Comparing different statistical models with different complexity 
Model Type Covariates SPSS syntax* 
1  Intermediate - Studied Polymorphisms 
- Diuretic drug excretion 
 




2 Most complex - Studied Polymorphisms 
- Diuretic drug excretion 
- 8 Polymorphisms reported 
earlier to predict renal functions 
 
GLM Vol_0_24 BY DIU WITH BFT_0_24 ACE 
ADD GNB ANP1 ANP2 NCC ENaCb ENaCg 
rs3857080_A 
/INTERCEPT=EXCLUDE/DESIGN= DIU 
BFT_0_24*DIU ACE ADD GNB ANP1 ANP2 
NCC ENaCb ENaCg rs3857080_A. 
3 Simple - Studied Polymorphisms 
 
GLM Vol_0_24 BY DIU WITH rs3857080_A 
/INTERCEPT=EXCLUDE/DESIGN= DIU 
rs3857080_A. 
* GLM is the general linear model function in SPSS, Vol_0_24 is the volume excreted between 0 and 24 hours (as an example of 
the studied phenotype), By DIU is referring to the way of stratifying the data (DIU was the study day), WITH followed by all the 
predictors including the new potential studied polymorphism, /INTERCEPT=EXCLUDE/DESIGN= is the model design where the 
interaction between the study days and the excreted drug amount was included in addition to all other old and new potential 
polymorphisms. In each model the data were copied in a number of lines as many as the studied polymorphisms and haplotypes 
with changing the name of the corresponding new predictor. 
 
2.4.2 Aldosterone receptor polymorphisms analysis  
The associations of the electrolyte excretions with the polymorphisms were analyzed by 
covariance analysis (ANCOVA) using the general linear model function of the software package 
SPSS® v21.0. Sodium and chloride excretion were analyzed as a composite endpoint termed 
sodium&chloride (Na&Cl); the separately analyzed results with sodium and chloride were 
comparable. For single regression analyses without further predictors in the model, 
polymorphisms were included solely as covariate. Secondly, in another statistical model, 
additional predictors were included as covariates: rs3857080 and Ile180Val together, the 
excreted amount of study drug and eight polymorphisms formerly reported to be implicated 
with diuretic effects in the two clinical studies (Vormfelde and Brockmoller, 2012; Vormfelde et 
al., 2006; Vormfelde et al., 2007; Vormfelde et al., 2010). The 25 mg and 100 mg 
hydrochlorothiazide days were pooled together, and the bumetanide with the furosemide days 
also for the analyses of explained fractions. Then, the study days were included as fixed factors. 
In the “models” option of the software, the terms of study days with amounts of study drugs 
excreted were added as interaction. P-values were presented unadjusted for the number of 
tests. 




2.5 DNA workflow 
 
2.5.1 DNA isolation from blood 
DNA was automatically extracted and purified from whole blood using the BioRobot® EZ1 and 
EZ1 DNA Blood 200 µl kit (Qiagen, Hilden) according to the manufacturer instructions. In 
principle, the kit involves magnetic particles. The DNA binds to the magnetic particles which 
would be separated by a magnet in the robot. 
 
2.5.2 DNA isolation from bacteria 
2.5.2.1 By chloroform extraction (Mini-prep) 
The used buffers for this DNA extraction are: buffer 1 (re-suspending buffer), buffer 2 (lysis 
buffer), buffer 3 (neutralizing buffer) and TE buffer (Table 6). 
Table 6: Buffers used in DNA isolation from bacteria by chloroform extraction (Mini-Prep) 
Buffer 1 (re-suspending buffer) pH 8.0   
Store at 4°C   
 Tris-HCl  50 mM 
 EDTA  10 mM 
 RNAse A (added after autoclaving the 
previous mixture) 
100 μg/ml 
   
Buffer 2 (lysis buffer)   
Store at room temperature   
 NaOH 200 mM 
 SDS 1% (w/v) 
   
Buffer 3 (neutralizing buffer) pH 5.5   
Store at room temperature   
 Potassium acetate 3 M 




   
TE buffer pH 7.5   
Store at room temperature   
 Tris 10 mM 
 EDTA  1 mM 
 
After performing electroporation to the bacteria cells [2.8.4], the bacteria were cultured on agar 
plate with the corresponding antibiotic [2.8.2]. Successful clones were picked up and cultured 
again over night with 5 ml LB medium [2.8.3] with the corresponding antibiotic. On the next 
day, 5 µl of each cultured clone was re-cultured on ¼ to ⅛ agar plate with the same antibiotic 
for further experiments like DNA isolation by solid phase extraction (Midi-prep) [2.5.2.2] or 
Making bacteria reservoir [2.8.5]. All cultured tubes were centrifuged at 4000 rpm with brake 9 
and accelerating 9 (Centrifuge 5810R; Eppendorf, Hamburg) for 10 minutes at room 
temperature. Supernatant was discarded and pellets were re-suspended in 250 µl buffer 1 and 
transferred into 1.5 ml Eppendorf reaction tubes. Cells were lysed by adding 250 µl buffer 2 and 
shaking well. The reaction was neutralized by adding 350 µl of buffer 3 and inverting 4-6 times. 
At this point, the denatured proteins and genomic DNA could be seen as white flakes. To purify 
the DNA from this mixture, several steps have been performed; the mixtures were centrifuged 
at 13000 rpm for 10 minutes (Biofuge pico; Heraeus, Hanau) at room temperature. The 
supernatant was transferred into new 1.5 ml Eppendorf reaction tubes and 500 µl of 
chloroform/isoamylalchohol (24:1 v/v) mixture was added to each tube with well shaking. The 
tubes were centrifuged at 13000 rpm for 5 minutes (Biofuge pico) at room temperature. The 
higher phase was transferred to a final well labeled 1.5 ml Eppendorf reaction tubes. To get 
plasmid DNA as pellets, 650 µl of pre-cooled isopropanol (at -20°C) was added with very well 
shaking. Tubes were centrifuged again at 13000 rpm for 15 minutes (Biofuge fresco; Heraeus, 
Hanau) at 4°C. The supernatant was discarded and the pellets washed with 500 µl pre-cooled (-
20°C) Ethanol 70%, then centrifuged at 13000 rpm for 8 minutes (Biofuge fresco) at 4°C. The 
supernatant was discarded and the pellets were left to dry at 37°C, then resolved in 50 µl TE 
buffer. The DNA extraction was qualified by running the samples on 0.8% agarose gel 




(1 µl plasmid DNA, 9 µl ddH2O, 2 µl loading dye 6X) and quantified using the photometric 
method [2.5.6.1].  
2.5.2.2 By solid phase extraction (Midi-prep) 
To get a higher amount and more pure extracted DNA plasmid for transfection purposes into 
eukaryotic cells (e.g. HEK293), The Compact Prep Plasmid Kit (Qiagen, Hilden) was used 
according to the manufacturer instructions. The protocol is based on a modified alkaline lysis 
procedure. A binding buffer is added to the cleared lysate to optimize the plasmid DNA binding 
to the provided column. Vacuuming is used to draw the cleared lysate and subsequent wash 
buffer through the column. The plasmid DNA is eluted again in small volumes (100 to 200 µl) by 
centrifuging. 
 
2.5.3 DNA isolation from agarose gel 
The QIAquick Gel Extraction Kit (Qiagen, Hilden) was used with the QiaCube robot (Qiagen, 
Hilden) according to manufacturer instructions. To recognize the pieces of the gel that contain 
the DNA, the agarose gel was placed on UV-light using transilluminator TI2 (Biometra, 
Göttingen), then sliced as wanted. The slices should not exceed 400 mg weight of 2% agarose 
gel. 
 
2.5.4 Polymerase chain reaction (PCR) 
Polymerase chain reaction is a process of DNA amplification under cell-free conditions using 
special oligonucleotides as primers. It consists of three major steps taking place one after each 
other several times in the same order (cycles). Each cycle consists of denaturation, annealing 
and an elongation step. In the denaturation step the temperature is increased till the two 
strands of DNA are separating from each other. In the annealing phase, each primer will bind 
selectively to one DNA strand. The polymerase, which should be in the reaction mix, will start 
making a new copy of the DNA in the elongation step. Repeating the cycles will lead to an 
increase in the number of the copied DNA in an exponential way. A final elongation step 
depending on the DNA fragment length is usually required. All the PCR reactions were 




performed using either the thermal gradient cycler (BioRad, Hercules, USA) or the thermal 
mastercycler (Eppendorf, Hamburg). 
2.5.4.1 Gradient PCR 
Each pair of primers has an optimal annealing temperature. For determination of the best 
annealing temperature, the gradient PCR procedure was performed. In general, PCR reaction 
under different annealing temperatures was performed for the same reaction mix at the same 
time, then the samples were run on 7% agarose gel to define the best conditions for the 
reaction. The same reaction was performed twice, one with Q-solution (comes with QIAGEN® 
Taq Polymerase Kit or with QIAGEN® Multiplex PCR kit), and the second without Q-solution. Q-
solution could help separating the two strands in a DNA fragment when it has a high GC content 
(guanine, cytosine content). The gradient PCR could be of special interest when making a 
multiplex PCR to amplify different fragments of the DNA using different primers in one reaction 
mix (Figure 8). An example of a gradient PCR reaction and program conditions is presented in 
Table 7.  
 
Table 7: Gradient PCR reaction and conditions 
Multiplex Mastermix  Multiplex Mastermix  
Without Q-solution Volume [µl] With Q-solution Volume [µl] 
2x QIAGEN Mastermix (Including 
Taq Polymerase, dNTP mix and 
magnesium chloride) 
5,5 
2x QIAGEN Mastermix (Including 
Taq Polymerase, dNTP mix and 
magnesium chloride) 
5,5 
10x Primer mix (2 µM each primer) 1,1 Q-solution 2,2 
H2O 3,4 
10x Primer Mix (2 µM each 
primer) 
1,1 
  H2O 1,2 
Total 10 Total 10 
    
DNA 1 DNA 1 
    
    




PCR conditions    
Denaturation 95oC 15 min  
Denaturation 94oC 30 sec 
35 Cycles Primers annealing Gradient 50-70°C 1 min 30 sec 
Elongation 72oC 2 min 
Final Elongation 72oC 10 min  




Figure 8: Agarose gel image of 5 PCR products, with and without Q-solution 
The optimal condition was defined as the condition with only those bands strongly appearing which were expected from the 
bioinformatics analysis. In this exact case, 6 DNA fragments were expected and they were all generated under 64.6°C annealing 
temperature. 
 
2.5.4.2 Using Taq polymerase 
Taq polymerase was used for genotyping purposes when amplifying several DNA fragments in 
one multiplex reaction, prior to the SNaPshotTM [2.6.1] or sequencing [2.6.2]. QIAGEN® 
Multiplex PCR kit which contains this polymerase was used always. Table 8 shows all the PCR 
primers used in this research for genotyping 39 polymorphisms in 9 different genes distributed 
to four batches. The oligo name is referring to the polymorphism of interest in the amplified 




DNA fragment. All oligonucleotides were designed using Oligo® v6.58 software (Molecular 
Biology Insights, Cascade CO, USA). 
Table 8: PCR primers used for genotyping 39 polymorphisms 
Oligo name 
Forward primer 
5’  3’ 
Reverse primer 































































































388 NEDD4L NEDD4L 2 








































































































302 NR3C2 MR 4 



















































288 NR3C2 MR 4 
 
2.5.4.3 Using Kod polymerase 
KOD HotStart DNA Polymerase (Novagen Merck, Darmstadt) was used for cloning purposes 
because of the high proofreading of this polymerase. PCR reactions using KOD polymerase were 
performed into the following reaction mix: 
Table 9: Standard KOD PCR reaction and conditions 
Standard KOD PCR reaction  Volume [µl] 
 10X Buffer  10 
 dNTPs (2 mM)  10 
 MgSO4 (25 mM)  4 
 Q-solution (optional)  20 
 Forward primer (100 µM)  1 
 Reverse primer (100 µM)  1 
 DNA (300 µg/ml)  2 
 KOD HotStart DNA Polymerase (1 u/µl)  2 
 ddH2O   to 100 
    




PCR conditions    
Denaturation 94oC 5 min  
Denaturation 94oC 15 sec 
35 Cycles Primers annealing 50-70°C 30 sec 
Elongation 72oC 1 min 30 sec 
Final Elongation 72oC 8 min  
Cooling down 8°C Forever  
 
Table 10 shows the two primers used to amplify the open reading frame of the transcription 
factor LHX4 from the pOTB7 vector (SourceBioscience Lifesciences, Nottingham, United 
Kingdom). The two primers were designed to have specific restriction sites for further ligation 
with the expression vector pcDNA3.1 (Invitrogen, Karlsruhe) [2.5.8] but still have the ATG in the 
forward primer as a starting codon and TTA in the reverse primer as a complimentary for the 
stop codon. 
Table 10: Designed primers for amplifying the open reading frame of LHX4 from pOTB7 vector 




2.5.5 Agarose gel electrophoresis 
The used buffers on the agarose gel electrophoresis are TBE buffer (pH 8.3) and 5X loading 
buffer (Table 11). 
Table 11: Buffers used in agarose gel electrophoresis 
TBE buffer pH 8.3   
Store at room temperature   
 Tris 100 mM 
 Boric acid 100 mM 
 EDTA 3 mM 




   
5X loading buffer   
Store at room temperature   
 Glycerol 30% (v/v) 
 EDTA 50 mM 
 Bromphenol blue 0.25% (v/v) 
 Xylene cyanol 0.25% (v/v) 
 
Agarose gel electrophoresis is a technique used usually to separate DNA fragments by their 
sizes. Agarose is forming a net matrix that leads to size separation of DNA. Gel electrophoresis 
could be used in the same context to trap the required DNA size prior to extracting the DNA 
from the gel [2.5.3]. Agarose concentration is ranging usually between 0.7% - 3% (w/v), 
depending on the DNA fragment size. To prepare the gel, the required agarose amount is 
weighed (Agarose Ultra Pure; Invitrogen, Karlsruhe) and dissolved into the TBE buffer using 
heating in the microwave. The gel would be cooled down for several minutes before adding 
0.5 µg/ml ethidium bromide (Merck, Darmstadt) and distributing it using a magnet stirrer. The 
gel mixture was poured into a gel tray with the required numbers of combs and left in room 
temperature for 20 minutes till it became solid. The solid gel was placed in a TBE buffer 
containing ethidium bromide (0.5 µg/ml) into the suited gel chamber. DNA samples were loaded 
after mixing them with the loading buffer (final concentration 1X). DNA ladders with 100 bp or 
1 kb (ABgene, Fermentas, St. Leon-Rot) were used as size standards. The electrophoresis was 
performed under 120 Volt using a ComPhor L Mini Gel chamber (Biozym, Hessisch Oldendorf), 
or under 150 Volt using PerfectBlue Gelsystem (PEQLAB, Erlangen). To visualize the 
electrophoretic results, Fluor-S™ MultiImager (BioRad, Hercules, USA) was used with the 
software Quantity One® S Version 4.3.1 (Bio-rad). 
 




2.5.6 DNA quantification 
2.5.6.1 Photometric quantification 
This method of DNA quantification is based on Beer–Lambert law: 
𝐴 = 𝛼 × 𝑙 × 𝐶 
Where A is the absorbance at wavelength of 260 nm, α is the absorption coefficient of the DNA 
(cm2/μg), L is the distance the light travels through the material (i.e., the path length, cm) and C 
is the solute concentration (ng/µl). To perform this measurement, 3 µl of the sample was placed 
on nanodrop cuvette (Implen, München) and the concentration was measured using 
BioPhotometer (Eppendorf, Hamburg). Absorbance ratio at 260/280 is giving a clue of the purity 
of the solution. All the samples with a ratio higher than 1.6 were considered pure enough for 
further experiments. 
2.5.6.2 Using PicoGreen® assay 
PicoGreen® assay is a very sensitive method of detecting double strand DNA (dsDNA) even in 
the presence of single strand DNA (ssDNA), RNA or free nucleotides. It can detect to as low as 
25 pg/ml of dsDNA. This very sensitive detection of dsDNA is of high value when preparing for 
genotyping techniques like TaqMan® or for library and template preparation prior to the 
Massive parallel sequencing (Next generation sequencing). This assay is based on the fact that 
the free cyanine dye (PicoGreen) does not fluoresce, but when it binds to the dsDNA it exhibits a 
more than 1000-fold fluorescence enhancement (485/535 nm; Excitation/Emission 
respectively). To perform the measurement the color reagent should be freshly prepared and 
stored for maximum one day at 4°C. The color reagent could be prepared by diluting PicoGreen 
dsDNA quantitation reagent (MoBiTec P-7589) 400 times into TE buffer (Table 6). 200 µl of the 
color reagent was pipetted into 96-wells Microtiter plate (Cat No 3603, Corning® Microtest, 
North Yorkshire, UK). The appropriate diluted samples (containing less than 20 ng/µl) were 
added to the wells in volume of 5 µl each. Standard dsDNA should be made from a stock human 
genomic DNA solution (10 ng/µl) by adding 0, 3, 5, 7, 10 µl from the stock solution in duplicates. 
The plate should be covered with an adhesive foil and the samples should be mixed by 
vortexing, then the plate was centrifuged and covered with aluminum foil to prevent the direct 
exposure to the light and incubated at room temperature for half an hour. The fluorescence was 
measured using Tecan Ultra® microplate reader and XFluor4 software. If any fluorescence value 




was not in the range between 150 and 32000 FUs, an appropriate dilution of the corresponding 
sample should be considered. 
 
2.5.7 Exonuclease and endonuclease restriction digestion  
2.5.7.1 For purification after PCR 
To purify DNA from the unincorporated dNTPs (deoxyribonucleotide) in PCR products, the 
recombinant Shrimp alkaline phosphatase 1 u/µl (rSAP, Affymetrix) was used to remove 5’-
phosphates from the dNTPS. Exonuclease I 20 u/µl (Fermentas, Thermo Scientific) was used to 
degrade the used primers as it hydrolyzes single-stranded DNA in the 3'→5' direction, releasing 
5'-mononucleotides. The following protocol was used: 
Reagent 
For 1 Sample 
[µl] 
rSAP (1 u/µl) 2,5 
ExoI (20 u/µl) 0,2 
10X rSAP Puffer 0,9 
PCR product 10 
Total 3 
  
37oC (Incubation) 1 hour 
Deactivation step 80oC (In PCR machine) 15 min 
8oC (In PCR machine) forever 
 
2.5.7.2 Analytical digestion 
Analytical digestion was used to check the fragmentation pattern of a DNA piece or a plasmid 
when it was cut at one, two or more specific positions that could be recognized by a specific 
restriction endonuclease enzyme. As an Example, a pOTB7 plasmid DNA containing sequence of 
the gene coding the transcription factor LHX4 (Source BioScience Lifesciences, Nottingham, UK). 
This plasmid has the size of 3534 bp and two cutting positions for EcorI which could lead to two 
pieces of DNA after the digestion with the last enzyme. The digestion mixture is composed of 
7 µl ddH2O, 1 µl buffer EcorI, 1 µl plasmid DNA and 1 µl EcorI (Fermentas, Thermo Scientific). The 
mixture was incubated in 37°C for one hour before running on 0.8% agarose gel (Figure 9). 





Figure 9: Analytical digestion for pOTB7+LHX4 plasmid DNA using EcorI restriction enzyme 
 
2.5.7.3 Preparative digestion 
Many of the endonuclease restriction enzymes cut the DNA to have sticky ends. Using that 
feature, we can use the preparative digestion prior to the ligation step with a complementary 
construct to the cut ends of the plasmid. The preparative digestion mixture consisted of 5 µl 
buffer according to the used restriction enzyme, 10 µl mini prep plasmid DNA, 5 µl digesting 
enzyme. The volume was completed to 50 µl with ddH2O. The mixture was incubated in the 
optimal temperature for the enzyme either for 3 hours or overnight, then 1 µl from the enzyme 
was added again for one more hour before running the sample on 0.8% agarose gel and extract 
the DNA from the gel 2.5.3]. 
 
2.5.8 Ligation 
This technique is usually used to insert a construct into the vector before performing 
electroporation to the bacteria cells. The idea is to bring the complimentary cut ends of the 
construct and the vector to each other. The complimentary ends could be generated either by 
preparative digestion [2.5.7.3] or synthetically. The ligation reaction is mediated by a DNA 




ligating enzyme (Ligate-ITTM Rapid Ligation Kit; USB, Staufen). The ligation mixture was 
prepared as the following protocol with a ratio insert:vector equal to 13:2 (v/v): 
 
Reagent For 1 Sample [µl] 
5x ligase buffer 14 
Plasmid vector 2 




Incubation (room temperature) 5-10 min 
Incubation (on ice) 5-10 min 
 
In order to test the ligation efficiency, the same reaction mixture should be prepared in parallel 
with ddH2O instead of the inserted construct. 
 
2.5.9 Dialysis 
This procedure was done to remove trace of salts from the ligation solution [2.5.8] prior to the 
electroporation [2.8.4] to transfer the plasmid into the bacteria cells. For that, the 20 µl ligation 
mixture was transferred carefully into the middle of a semipermeable membrane (Dialyse filter 
VSWP01300, Millipore, Schwalbach). The membrane should be placed already on the surface of 
ddH2O into a petri dish without covering upper face with the water. After 30-45 minutes, the 
solution was removed and transferred to a new 1.5 ml Eppendorf tube. The mixture was 
concentrated under vacuum and heat. For that, the Eppendorf tubes’ caps were opened and 
placed in SpeedVav Plus® SC110A vacuum centrifuge (Schütt, Göttingen) after heating it. The 
centrifugation was started under vacuum (200 mbar, Membran-Vacuumpumpe, Vacuubrand, 
Wertheim) for 8 minutes. The remained DNA on the walls of the Eppendorf tubes should be 
reconstituted by pipetting and washing the tube’s wall using the residual liquid. 




2.5.10 Reverse transcription 
In order to assess the transcription level of any gene (e.g. quantitative PCR [2.5.11]), RNA should 
be reversely transcribed into cDNA (copy or complimentary DNA) for stability reasons and 
easiness of further amplification and other procedures. For that, all the RNA-containing samples 
were normalized to a concentration of 1 µg/µl. Then 1 µl of random hexanucleotide primers 
(dN6; Roche, Mannheim) were added to the 1 μg RNA samples and incubated at 72°C for 10 
minutes. The samples were left on room temperature to cool down slowly for one hour. 
Meanwhile, the reverse transcriptase mastermix (RT-Mastermix), which contains the Super 
ScriptTM II reverse transcriptase (Invitrogen, Karlsruhe), could be prepared as the following: 
 
RT-Mastermix Volume (per sample) [µl] 
5x Superscript RT buffer 6 
DTT (0.1 M) 3.5 
dNTPs (10 mM) 1 
RNase Inhibitor (USB) 0,5 
Super Script™ II (200 u/μl) 0.25 
Total volume 11.25 
 
A total of 11.25 µl from the RT-Mastermix was added to each samples and the reverse 
transcription was started by incubation at 42°C using either the thermal gradient cycler (BioRad, 
Hercules, USA) or the thermal mastercycler (Eppendorf, Germany) for one hour. An expected 
concentration of 2-10 ng/µl of cDNA could be achieved by adding 70 µl ddH2O to each sample. 
 
2.5.11 Quantitative PCR 
The transcription levels of both aldosterone receptor gene (NR3C2) and with-no-Lysine 4 
(WNK4) were evaluated using the quantitative PCR (real-time PCR). The housekeeping gene 
used as endogenous control (internal standard) was the Human TBP (TATA-box binding protein) 
(VIC/MGB Probe, Primer Limited; Applied Biosystems, Darmstadt). For that, 3 µl of already 
prepared cDNA [2.5.10] were added to 15 µl of the gene expression mastermix (per sample and 
well) in a 384-wells plate (Thermo Fast Plate 384 PCR, ABgene, Epsom, UK). The plate was 




covered with a special optical clear foil (Adhesive PCR foil seals; ABgene, Epsom, UK). The gene 
expression mastermix was prepared as the following: 
 
Reagent (per sample) Volume [µl] 
2x qRT-PCR Mastermix (PrimerDesign Ltd Precision OneStepTM, United Kingdom) 9 




Table 12: Used gene expression assays (Applied Biosystems, Darmstadt) 






The quantitative PCR was performed using Applied Biosystems 7900HT Fast Real-Time PCR 
System under the following conditions: 
 
Phase Duration Temperature  
Activating uracil n-glycosylase 2 Min 50°C  
Activating Taq Polymerase 10 Min 95°C  
Denaturation 15 Sec 95°C 
40 Cycles 
Primer annealing 1 Min 60°C 
 








The relative expression of the studied genes was calculated using the equation: 
𝑅𝑒𝑙𝑎𝑡𝑖𝑣𝑒 𝑒𝑥𝑝𝑟𝑒𝑠𝑠𝑖𝑜𝑛 = 2−𝑑𝐶𝑡 
Or 
𝑅𝑒𝑙𝑎𝑡𝑖𝑣𝑒 𝑒𝑥𝑝𝑟𝑒𝑠𝑠𝑖𝑜𝑛 = 2−(𝑑𝐶𝑡−𝑀𝑎𝑥𝑖𝑚𝑢𝑚 𝐶𝑡 𝑏𝑒𝑡𝑤𝑒𝑒𝑛 𝑡ℎ𝑒 𝑠𝑎𝑚𝑝𝑙𝑒𝑠) 
𝑑𝐶𝑡 = (𝐶𝑡𝑚𝑒𝑎𝑠𝑢𝑟𝑒𝑑 𝑔𝑒𝑛𝑒 𝑖𝑛 𝑡ℎ𝑒 𝑠𝑎𝑚𝑝𝑙𝑒 − 𝐶𝑡ℎ𝑜𝑢𝑠𝑒𝑘𝑒𝑒𝑝𝑖𝑛𝑔𝑔𝑒𝑛𝑒 𝑖𝑛 𝑡ℎ𝑒 𝑠𝑎𝑚𝑒 𝑠𝑎𝑚𝑝𝑙𝑒) 
Where Ct is the cycle number at which the fluorescence emission exceeds the fixed threshold 
level (defined automatically by the software) and is inversely proportional to the expression 
level of the target gene. 
 
2.6 Sequencing and genotyping workflow 
 
2.6.1 Genotyping by the Single Nucleotide Primer Extension Method SNaPShotTM 
SNaPShotTM is a SNP genotyping method which refers to a single nucleotide extension at the 
position of the polymorphic base. To achieve a single nucleotide extension only, the use of 
fluorescently labeled dideoxyribonucleotide triphosphate (ddNTPs) is required in a SNaPShot 
PCR reaction (SNaPShot reaction mix: ABI PRISM® SNaPshot™ Multiplex Kit, Applied Biosystems). 
ddNTPs are dNTPs lacking (–OH) group at the 3’ position which make them not suitable for 
further DNA extension. Two major steps are required for this method (Figure 10). The first is to 
amplify the DNA fragments that include the polymorphism(s) [2.5.4.2; Table 8]. The second is to 
design the SNaPShot primers that stop exactly one nucleotide before the genotyped 
polymorphism, where the complimentary fluorescent ddNTP could make a single nucleotide 
extension and could be detected by suitable laser detector after the electrophoresis. As the 
electrophoresis is separating the fragments depending on its length, it is possible to genotype 
up to 30 polymorphisms under optimal conditions with efficient results. 
 





  Figure 10: The two major steps for SNaPShotTM genotyping method 
The upper part illustrates the PCR for amplification and the lower part shows the single nucleotide extension reaction ending 
with the incorporation of a fluorescently labelled ddNTP at the polymorphic base to be analyzed. 
 
In details, after performing the purifying step [2.5.7.1] for the PCR products that include the 
polymorphisms [2.5.4.2], SNaPShot PCR reaction was performed under the following conditions 
in a 384-well PCR Plate (FrameStar®; 4titude, Dorking, UK) (Table 13): 
 
Table 13: SNaPShot PCR reaction and conditions 
Reagent Volume per sample [µl]   
SNaPShot reaction mix 0.5 – 2   
Pooled primers mix (0.5-2 µM each) 0.5   
ddH2O To 3   
PCR products (DNA fragments) 2   
Total  5   
    
    




SNaPShot PCR conditions    
 Temperature Duration  
Initial Denaturation 96°C 2 Min  
Denaturation 96°C 10 sec 
26 Cycles Primers annealing 50°C 5 sec 
Elongation 60°C 30 sec 
Cooling down 8°C Forever  
 
After the SNaPShot PCR, the samples underwent another purification step by incubating each 
with 1 µl from a mixture 1:1 (v/v) of fast alkaline phosphatase and the respected-buffer (Fast-
AP; Fermentas, St. Leon-Roth) at 37°C for one hour to destroy the remaining unincorporated 
fluorescently labeled ddNTPs. The enzyme should be deactivated by incubating the samples at 
75°C for 15 minutes. At this point, samples could be stored at 4°C or prepared for the 
sequencing and analysis. For that, 1 µl from the samples is transferred to a 96-well sequencing 
plate containing 10 µl from the sequencing mastermix (Table 14). The plate was incubated at 
95°C for 5 minutes then placed on ice immediately until cooling down. The plate was installed 
into its adapter for 3130xl Genetic Analyser (Applied Biosystems, Darmstadt) and data were 
analyzed using Gene mapper v3.7 software® (Applied Biosystems, Darmstadt). 
 
 
Table 14: Sequencing mastermix for SNaPShot® 
Reagent Volume per sample [µl] 
Formamid (Hi-DiTM Formamid, Applied Biosystems) 10 








Table 15: SNaPShot® primers used in genotyping 39 SNPs 
rs-number Gene SNaPshot Primer 
Primer 
length 
Allele1 Allele2 Batch No. 
rs765250 WNK1 AAGACATGCTCACCAAAACA 20 G A 1 
rs1057293 SGK1 GGACACATTGTCCTTACTGA 20 C T 1 
rs2277869 WNK1 gatcGGCTTCCCAGYTCATCCTCT 24 C T 1 
rs7880501 WNK3 gatcgatcTTCAAATTTCTTGTACAGTA 28 C T 1 
rs2107614 WNK1 gatcgatcgatcGAAGAGTTGAGGGGAAATGG 32 G A 1 
rs3021285 WNK3 gatcgatcgatcgatcACTCTACTTACTGGTGGGGC 36 C T 1 
rs1159744 WNK1 gatcgatcgatcgatcgCTTTACTGATATTCTCTATTTGTTGAG 44 G C 1 
rs61755606 WNK4 gatcgatcgatcgatcgatcgatcgatcGTCTGGTTTCTAATACCAGACTTTAGA 55 G A 1 
rs77012584 WNK4 AGGCCTCTGACCACTGACCT 20 C T 2 
rs457661 OXSR1 GCTGCCGCCGTCATGTCCGA 20 G A 2 
rs2846679 KCNJ1 gatcgaAGCCTTTCCCCCAGACCTTC 26 C T 2 
rs1010069 CLCNKA gatcgaAGGACAGCCCTGGGGGTTGG 26 G A 2 
rs113919536 OXSR1 gatcgatcgatcAGCTGTTTTTGCTGGCTCTG 32 C A 2 
rs4149601 NEDD4L gatcgatcgatcgatcgaAAAGTCTTACCGAGTGTTAC 38 C T 2 
rs3088353 WNK1 gatcgatcgatcgatcgatcgaCGAACCCGCCCGGCCGCGGT 42 G T 2 
rs2288774 NEDD4L gatcgatcgatcgatcgatcgatcgatcgAAATGCCACTCTGAAAATAC 49 G A 2 
rs77879367 WNK4 gatcgatcgatcgatcgatcgatcgatCGCAGCCTAACCCTGGCCAGAGTGGCTG 55 G T 2 
rs75596106 WNK4 gatcgatcgatcgatcgatcgatcgatcgatcgatcgatcgaGACGATGTTGGGGTGCTGCA 62 G C 2 
rs76937254 KCNJ1 gaGATCAATATCAACTTTGTAG 22 C T 3 
rs2070951 NR3C2 gatcgaGGTAGCCTTTGGTCTCCATC 26 G C 3 
rs35295772 OXSR1 gatcgatcCTTGGTTTCTTGTGAACCTG 28 A T 3 
rs3021280 WNK3 gatcgatcgatcTCAGGGCACCGGCAGGGCTA 32 G T 3 





gatcgatcgatcgatcgatcgaAGATCCTTTCTCACAGCATG 42 C T 3 
rs6599079 OXSR1 gatcgatcgatcgatcgatcgaTGGTTGGTGCTCTCTGCAAT 42 G A 3 
rs9493857 SGK1 gatcgatcgatcgatcgatcgatcgatcgCTAAGTAGTTGATGAAACTA 49 C T 3 
rs76640813 KCNJ1 gatcgatcgatcgatcgatcgatcgatcgTTTTCTCTGGAGACTCAAGT 49 G A 3 
rs3857080 NR3C2 gatcgatcgatcgatcgatcgatcgatcgatcgaGTTTTCCAGAGAACTGAGTGTC 56 G A 3 
rs5522 NR3C2 gatcgatcgatcgatcgatcgatcgatcgatcgatcgatcgTGAATGGTGGCGTCATGCGCGCC 64 G A 3 
rs3021284 WNK3 gatcgatcgatcgatcgatcgatcgatcgatcgatcgatcgatcGATAACCCAATTTACCTCTGTACAAA 70 T A 3 
rs11737660 NR3C2 ATCACACCACCTTTCATGCC 20 G A 4 
rs5534 NR3C2 CTTTCCAAGATCAGAAGGGAA 21 C T 4 
rs10519963 NR3C2 gatGAGCTCTCTCTTACCCTTTTAAAGA 28 C T 4 
rs4835493 NR3C2 gatcgaTGAGGGATATGGAGATATTAGG 28 G A 4 
rs1040288 NR3C2 gatcgatcgatcgaTGTGTGCCAAGCTGAGTAAT 34 G C 4 
rs6810951 NR3C2 gatcgatcgGACCTCATCCTCTACTCTGGAATAAGTCAA 39 C A 4 
rs11099680 NR3C2 gatcgatcgatcgatcgatcgatcTGAGGCATATGGCAACATAG 44 C T 4 




rs3846329 NR3C2 gatcgatcgatcgatcgatcgatcgatcgGGCTGCTCACCTCCACAGAT 49 C A 4 
rs11099681 NR3C2 gatcgatcgatcgatcgatcgatcgatcgatGTGTAAGATTGCTGGTGTTTCTTT 55 C T 4 
Y refers to C or T as the IUPAC codes (in the SNaPShot primer for rs2277869) 
 
2.6.2 Dideoxy chain termination (Sanger) sequencing 
The chain termination sequencing using capillary sequencer is derived originally from the work 
of Sanger and Coulson in 1975. The difference here is the use of fluorescently labeled ddNTPs in 
one reaction only. Each of the ddNTPs can give specific color which leads to recognize the end of 
the sequence. The reaction mix should contain also dNTPs to extend the DNA strand through 
the sequencing PCR reaction. On each extension procedure, there is a chance to add one of the 
fluorescent ddNTPs and end the extension. The differently sized DNA fragments could be 
separated by capillary electrophoresis. The end of each DNA fragment sequence could be 
detected by laser detector supplied with the sequencer. The huge number of extended DNA 
fragments with different sizes through the sequencing PCR reaction will lead to distinguish all 
the probable nucleotides through the sequenced DNA fragment. This method is efficient to 
sequence DNA fragments between ~60 base pairs and maximum several hundreds of base pairs 
in one run. 
In details, DNA from mini-prep directly [2.5.2.1] or after purification step of previous PCR 
reaction [2.5.7.1] is treated with the sequencing master mix and sequencing PCR is performed in 
a 384-well PCR Plate (FrameStar®; 4titude, Dorking, UK) as the following (Table 16): 
 
Table 16: Sequencing PCR reaction and conditions 
Sequencing PCR Mastermix Volume per sample [µl]   
ddH2O  2,25   
DMSO (Dimethyl sulfoxide) 0,25   
Primer (10 µM) 0,5   
BigDye® terminator v1.1 (Applied 
Biosystems, Darmstadt) 
1   
Total  4   
DNA 1   




    
Sequencing PCR conditions    
 Temperature Duration  
Initial Denaturation 94°C 2 Min  
Denaturation 96°C 15 sec 
26 Cycles Primers annealing 56.5°C 15 sec 
Elongation 60°C 4 min 
Final end-terminal elongation 72°C 7 min  
Cooling down 8°C Forever  
 
To remove the unincorporated dNTPs and ddNTPs from the reaction mix, the samples should 
undergo a purification step through Sephadex G50 superfine (Amersham Bioscience, Freiburg). 
For that, 35 mg of sephadex is transferred to a 96-well filter plate (MAHV-N45, Millipore, 
Schwalbach) and incubated at room temperature after adding 300 µl ddH2O for three hours. 
After that, the excess water was removed by centrifuging for 5 minutes at 700 rpm (Centrifuge 
5810 R; Eppendorf, Hamburg). Again, 150 µl of ddH2O was added and the sephadex was 
incubated at room temperature for half an hour. The excess water was removed by centrifuging 
also (700 rpm; RT). Finally, the sephadex plate was placed over a sequencing plate and the 
samples were transferred to the sephadex wells. The samples were collected in the sequencing 
plate after centrifuging for 5 min at 700 rpm and room temperature. Samples were sequenced 
using the 3130xl Genetic Analyser (Applied Biosystems, Darmstadt) and data were analyzed 
using Sequencing Analysis Version 5.2 software® (Applied Biosystems, Darmstadt) then with 
Staden Package v4.0 (Cambridge, UK) or DNASTAR® v11.2 (Madison WI, USA). 
Primers which were used to sequence the vectors in this research (pGL3promoter, pOTB7 and 




















2.6.3 Massive parallel sequencing (Next generation sequencing) 
The massive parallel sequencing (also called Next generation sequencing NGS, High-throughput 
sequencing or Deep sequencing) is a method where one can sequence the DNA in mega base 
pairs scale, giving the possibility to scan a number of genes for a number of participants and 
pooling all the samples from different participants in one run without the need to treat them 
separately alike the capillary sequencing. The difference in the number of the read bp per run 
differs between the instruments and techniques, but in general it ranges between 100 Mbp and 
600000 Mbp.  
As a new technique in the institute of clinical pharmacology, the Ion Personal Genome 
Machine™ Sequencer (PGM™; Life technologies, Darmstadt) was used in this work to sequence 
all the exon regions in the WNK4 gene for all the participants in both clinical studies. The Ion 
PGM™ Sequencer (Ion Torrent) chemistry is based on ion semiconductor sequencing. The ion 
semiconductor sequencing is based on the detection of hydrogen ions that are released after 
each incorporation of a new dNTP that is complementary to the template DNA.  
The typical workflow in the massive parallel sequencing usually includes: target enrichment, 
library preparation, template preparation, sequencing and data analysis. 




2.6.3.1 Target enrichment 
First of all, the idea was to use the advantage of the high read numbers of the technique to 
sequence all the DNA samples from both clinical studies together. The pooling criteria was set as 
the Sodium and Chloride excretion between 0 and 24 hours. For that, each clinical study was 
divided into two groups; low and high sodium and chloride eliminators. To have these two 
groups in the first clinical study on loop diuretics, the excretion of sodium and chloride under 
each drug was given a sorting code, then the participants were sorted upon the median 
numbers coming from the sorting codes for each of the three drugs. The same was applied for 
the second clinical study but with the numbers coming only from hydrochlorothiazide 25 and 
100 mg days. The DNA samples were normalized using QIAgility® pipetting machine (QIAGEN®) 
then pooled as defined into four final samples (each contains DNA which is coming from around 
50 participants). 
One of the limitations of the ion torrent sequencing techniques is that the amplicons’ length 
should not exceed 300 bp as maximum. For that it was necessary to amplify the exons of WNK4 
in two separate pools for each sample to cover the whole wanted area. Primers were designed 
using Ion AmpliSeq™ Designer webtool from life technologies. A total of 50 amplicons divided 
into two pools for each group of the four pooled sample groups were covering finally the 




Figure 11: WNK4 gene with the covered regions by the target enrichment. 
The upper blue panel is the final covered regions. The red one is the missing regions from the originally designed and wanted 
regions (in green). The WNK4 19 exons reference is on dark blue under the three last panels. The figure was produced using the 
“loading custom track” function in the UCSC genome browser (http://genome-euro.ucsc.edu/index.html). 
 
 





The final 8 pools were normalized to have 10 ng of total DNA for library preparation. An 
overview of the pooling procedure and target enrichment are depicted in (Figure 12): 
 
Figure 12: Target enrichment for the NGS workflow 
The pipetting machine icon was taken from the company website (Qiagility; Qiagen, Hilden) 
(http://www.qiagen.com/products/catalog/automated-solutions/assay-setup/qiagility) 
 
2.6.3.2 Library preparation 
Library preparation was performed according to the manufacturer’s user guide for Ion 
AmpliSeqTM Library Kit 2.0 (Life technologies), catalog numbers 4475345, 4478378, 4478379, 
publication part Number MAN0006735 and revision date 8 June 2012. The final quantification of 
the prepared libraries was performed according to the manufacturer’s user guide for Ion Library 
Quantitation Kit (Life technologies), catalog number 4468802, publication part number 4468986 
Rev. C and revision date August 2011. 
In general the library preparation implements several enzymatic steps after the target 
enrichment for end repair, adapter ligation, nick repair and PCR amplification. In between there 




is also a number of purification steps mostly using the magnetic beads and quality control steps 
by regular quantification of the libraries. 
After preparing the libraries, the barcodes and adapters would be ligated to the DNA fragments. 
The 8 different pools from the four sample groups were pooled together for further treatment 
for the template preparation. 
2.6.3.3 Template preparation 
Template preparation was performed according to the manufacturer’s quick reference for Ion 
OneTouchTM 200 Template Kit v2 (Life technologies), publication part number 4478371 Rev. B 
and revision date 13 June 2012. 
In general, the template preparation begins with generating an emulsion from the pooled 
library products. In this step, on average in each emulsion drop only one DNA molecule should 
be trapped with one Ion OneTouchTM 200 Ion SphereTM Particle (ISP). Then performing emulsion 
PCR using the OneTouchTM instrument for preparing template-positive ISPs. The next step would 
be to recover the positive ISPs through enrichment procedure using Ion OneTouchTM ES. The 
enrichment involves using magnetic beads which have streptavidin and bind to the positive ISPs 
(biotin-streptavidin bind) then isolating them using a magnet. After that, the magnet beads 
would be washed out leaving the positive ISPs with single strands DNA.  
2.6.3.4 Sequencing and data analysis 
Sequencing was performed according to the manufacturer’s quick reference for Ion PGMTM 200 
Sequencing kit (Life technologies), publication part number 4474596 Rev. A and revision date 17 
February 2012. The used chip was Ion 316TM. Data were analyzed mainly by two software: 
DNASTAR® v11.2 (Madison WI, USA) and Integrative Genomics Viewer v3.4.51874 (Broad 
institute, Cambridge MA, USA) with Torrent Variant Caller Plugin v3.4. 
 
2.7 DNA-protein binding 
2.7.1 Electrophoretic mobility shift assay (EMSA) 
Nuclear protein extracts from HEK293 cells were obtained by the Dignam method (Dignam et 
al., 1983) followed by a purification step with ammonium sulfate (kindly provided by Dr. Kristin 




Bokelmann). The extraction was done at 4°C under pH=7.9 to prevent denaturation of the 
proteins. Quantification of the protein amount was done by the Bicinchoninic Acid Assay (BCA). 
The required short double strand DNA segments were obtained by placing the mixture of the 
complementary oligonucleotides in Table 18 inside 1.5 ml Eppendorf tube at 95°C water and 
leaving it cooling down to the room temperature. 
Electrophoretic mobility shift assay (EMSA) was performed as the following. 2 pmol/µL of the 
annealed oligonucleotides were radiolabeled by incubation with Klenow-Fragment (MBI-
Fermantas, St. Leon-Roth) at 37°C for 1 hour with [α-
32
P]dCTP (Hartmann Analytic GmbH, 
Braunschweig) and the other three dNTPs (each 1 µM) (Table 19). For purification from the 
unbound [α-
32
P]dCTP, mini Quick Spin Oligo Columns (Roche, Germany) were incubated first for 
one hour at room temperature, then homogenized by vortexing and centrifuged to remove the 
excess water at 3200 g for two minutes at room temperature (Biofuge 15 R; Heraeus, Hanau). 
The labeled samples were added to the columns and centrifuged again (3200 g, 4 minutes, RT) 
(Biofuge 15 R; Heraeus, Hanau). For the binding reaction, an amount of 20 µg from the nuclear 
protein extracts was pre-incubated for 10 min on ice with 18 µl reaction mixture consisting of 
binding buffer, poly dI-dC 1 µg/µL (poly deoxyinosinic-deoxycytidylic) and ddH2O. The 
radioactive probes (30000 CPM) were added and incubated with the mixture for 10 minutes 
(Table 20). The samples were mixed with 6x loading buffer (Table 20) before running the 
samples on a 5% native non-denaturing polyacrylamide gel equilibrated in 0.5% TBE-buffer at 
180 Volt for one hour (Table 21). The gel was dried by placing it on Whatman papers (Nr. 2668, 
Schleicher und Schüll, Dassel) over the gel-drying-system at 80°C for one hour (DrygelSr; Hoffer 
scientific instruments, San Francisco, USA). The dried gel was incubated overnight with Fujifilm 
BAS1500 plate and the radioactive signals were visualized using Phosphor Imager (Raytest, 
Sprockhövel) and the software BASreader and AIDA (Version 4.15.025, Raytest, Sprockhövel). 
To determine the exact amount of radioactivity in the labeled samples, 1 μl of the sample was 
mixed with 4 ml of safety scintillator solution (Aquasafe 500 Plus; Zinsser Analytic, Berkshire) 
and measured by the scintillation counter LS1801 (Beckman, München). 
 
 







Table 18: Annealing mixture for oligonucleotides used in EMSA 
Reagent Volume [µl] 
Oligo_f (100 μM) 1 
Oligo_r (100 μM) 1 
NaCl (0.5 M) 1 
ddH2O to 50 
 
 
Table 19: Labeling mixture with [α-32P]dCTP 
Reagent Volume per sample [µl]  
ds-Oligonukleotide (2 pmol/μl) 1  
dNTPs (A, G, T each 1 mM)  1  
10x Klenow-Buffer  2  
ddH2O   12  
[α-
32
P]dCTP (10 μCi/μl)  2 
Add in the radioactive area 
Klenow-Fragment (1 u/μl)  2 
 
 
Table 20: EMSA binding reaction and buffers 
4x Binding buffer pH 7.9: 
Store at 4°C  
 
 
 HEPES pH 7.8 80 mM 
 EDTA pH 8 4 mM 
 DTT  2 mM  
 Glycerol  40%  
 KCl  560 mM  




   




 4x Binding buffer 5 μl 
 Nuclear protein extracts 20 μg  
 Poly dI-dC (1 μg/μl)  2 μl  
 ddH2O  To 18 μl 
   
6x Loading buffer: 
Store at -20°C  
 
 
 Glycerol 87% 30% (v/v) 
 Bromphenol Blue  0.25% (w/v)  




Table 21: 5% native non-denaturing polyacrylamide gel 
5% Polyacrylamide gel:    
40% (w/v) Acrylamide/Mix 37:5:1 4.4 ml  
5x TBE  3.5 ml   
ddH2O 27 ml   
APS 10% (w/v)  350 μl  
Gel forming reagents 
TEMED  35 μl  
   
5x TBE Buffer pH 8:   
Tris  450 mM   
Boric acid 450 mM   
EDTA  10 mM   
 




2.7.2 Cold competition 
Cold competition was performed either to define the specific binding pattern between the 
different alleles of the polymorphism, or to check the competition with the known consensus 
(binding sites’ sequences) of some transcription factors. For that, 10- to 50-fold of the unlabeled 
competitor probe was added. Quantification of the signals was done using Quantity One v4.2.1 
software (Bio-Rad, München). Cold competition was done with the known consensus for the 
most probable transcription factors suggested with TRANSFAC® database (AP1, BARX1, GBX2, 
LHX4, MSX1, SOX4, and TBX5). In case of the competition, either the intensity of the band could 
be decreased or the band itself might disappear. 
 
2.7.3 Super shift assay 
For the super shift assay we used 2 µL anti-LHX4 antibody which provided as a suspension in 
50% ammonium sulfate and phosphate buffered saline (Product number L 5042, Sigma-Aldrich, 
St. Louis, USA). When the determined transcription factor binds to its specific antibody, either 
the intensity of the band could decrease or the band itself might be shifted up. 
All the oligonucleotides in this work (Eurofins MWG Synthesis GmbH, Ebersberg) which were used 
in EMSA experiments, cold competition and super shift are listed in Table 22. 
 
Table 22: Oligonucleotides used for electrophoretic mobility shift assays (EMSA) 
Oligo Name sequence 
rs3857080  
rs3857080 major allele (G) – f * gatcCAGAGAACTGAGTGTC-G-ATTTTAATGTTTTTTTC 
rs3857080 major allele (G) – r ** gatcGAAAAAAACATTAAAAT-C-GACACTCAGTTCTCTG 
rs3857080 minor allele (A) – f gatcCAGAGAACTGAGTGTC-A-ATTTTAATGTTTTTTTC 
rs3857080 minor allele (A) – r gatcGAAAAAAACATTAAAAT-T-GACACTCAGTTCTCTG 
rs3857080 Mutated minor allele (A) - f gatcCAGAGAACTGAGTGTC-A-GGGG-TAATGTTTTTTTC 




rs3857080 Mutated minor allele (A) - r gatcGAAAAAAACATTA-CCCC-T-GACACTCAGTTCTCTG 
LHX4  
Lhx4 Consensus - f gatcGTATGAATC-AT-TAAT-TG-ACAACATAT 
Lhx4 Consensus - r gatcATATGTTGT-CA-ATTA-AT-GATTCATAC 
Lhx4 Mutated - f gatcGTATGAATCAT-CCCC-TGACAACATAT 
Lhx4 Mutated - r gatcATATGTTGTCA-GGGG-ATGATTCATAC 
rs11099680 as negative control  
rs11099680 major allele (T) - f gatcGCATATGGCAACATAG-T-GTAATACTTGGAAGAC 
rs11099680 major allele (T) - r gatcGTCTTCCAAGTATTAC-A-CTATGTTGCCATATGC 
rs11099680 minor allele (C) - f gatcGCATATGGCAACATAG-C-GTAATACTTGGAAGAC 
rs11099680 minor allele (C) - r gatcGTCTTCCAAGTATTAC-G-CTATGTTGCCATATGC 
* f = forward, ** r = reverse 
 
2.8 Working with bacteria 
2.8.1 Bacteria growth medium 
Luria-Bertani (LB) complex medium was used as a growth medium for the Escherichia coli 
bacteria strain One Shot® TOP10 Electrocomp™ E. coli (Invitrogen, Karlsruhe). For preparation of 
the LB-solution, 10 g Tryptone, 5 g Yeast extract and 5 g NaCl were dissolved in ddH2O to a final 
volume of one liter. For preparation of solid LB-medium, 14 g agar (AppliChem, Darmstadt) 
could be added. The last mixture should be autoclaved and stored either at 4°C as solution or till 
it reaches ~50°C, then it could be distributed under sterile conditions into the petri dishes. 
When necessary, an antibiotic as a selection marker could be added after the autoclaving step 
as the following (Table 23): 




Table 23: Concentrations of the used antibiotics 
Antibiotic Concentration in the stock solution 
stored at -20°C 
Working concentration (Dilution) 
Ampicillin 
(Sodium salt) 
50 mg/ml in water 100 µg/ml (1/500) 
Chloramphenicol 34 mg/ml in ethanol 170 µg/ml (1/200) 
 
2.8.2 Bacteria cultivation on agar plates 
This cultivation was usually done after transformation by electroporation [2.8.4] or for 
propagation of the clones (e.g. from bacteria suspension before starting mini-prep for making 
midi-prep). For that the bacteria suspension was distributed on the agar plate in petri dish, 
which could be supplied with the corresponding antibiotic as selection marker. For the 
distribution, a sterile Pasteur pipet treated with the flame was used. The agar plates were 
incubated at 37°C with the cover facing down overnight. Next day, the plates could be sealed 
using Parafilm (Brand; Wertheim) and stored at 4°C for maximum one month. 
 
2.8.3 Bacteria cultivation in solution 
This cultivation was usually done to get the bacteria suspension necessary for mini-prep 
[2.5.2.1] or midi-prep [2.5.2.2]. For mini-prep, a picked up clone from an agar plate was 
suspended in 5 ml LB-medium supplied with the corresponding antibiotic into 15 ml sterile tube 
(Greiner, Frickenhausen) and incubated at 37°C overnight with 250 rpm shaking using K2 260 
basic-shaker for bacteria (Ika, Staufen). The tube should be placed on a slant position to 
increase the surface for oxygen exchange and the cap should not be tightened for the exchange 
of the air also. For midi-prep, 30 ml of LB-medium in special 500 ml autoclaved bottle could be 
used as described above. Sometimes it was better to start cultivating the bacteria in 5 ml LB-
medium for some hours before transferring a small amount of the suspension to the 30 ml in 
the bottle for midi-prep. 




2.8.4 Transformation by electroporation 
This procedure was done to insert a certain plasmid into the bacteria cells so they can 
reproduce this plasmid again and again. The circular plasmid DNA with the insertion should be 
prepared first by a number of steps explained previously like preparative digestion [2.5.7.3], 
ligation [2.5.8] and dialysis [2.5.9]. Electroporation mix should be prepared by adding 30 µl 
ddH2O, 10 µl from the One Shot® TOP10 Electrocomp™ E. coli (Invitrogen, Karlsruhe). The mix 
was transferred into pre cooled Electroporation cuvette (PeqLab, Erlangen), then 0.8-1 µl of the 
final prepared dialyzed plasmid was mixed by pipetting. The electroporation was performed 
using Gene Pulser II (Bio-Rad, Hercules, USA) under the following conditions: 2.5 kV, 25 μF and 
200 Ω for about 5 milliseconds. If the electroporation was successful with no electric shock-sign, 
800 µl of pre-warmed LB-medium was added and incubated at 37°C for ~one hour. Finally, a 
volume of 50- and 200 µl of the suspension was cultivated on two agar plates with the suitable 
selection marker [2.8.2]. 
 
2.8.5 Making bacteria reservoir (Stock) 
After getting positive clones with the required insertion, a stock solution from the generated 
bacteria was prepared for long-term storage. For that, 600 µl from a fresh-5 ml bacteria 
suspension overnight-cultured should be mixed with 600 µl of sterile 50% glycerol solution. The 
stock should be transferred immediately to -80°C where bacteria could be stored for several 
years into it. 
 
2.9 HEK293 cells workflow 
2.9.1 Culturing conditions 
HEK293 Cell Line (DMSZ, Braunschweig) is derived from the human embryonic kidney cells and 
was used in this research for performing the luciferase reporter gene assay. Cells were cultured 
in DMEM medium supplied with 10% FCS (fetal calf serum) and 1% penicillin/Streptomycin (100 
u/ml and 100 µg/ml solved in distilled water respectively). The medium was always pre-warmed 
in a water bath at 37°C (CO2-Incubator BBD 6220; Heraeus, Hanau). The cells were sub-cultured 
every 3-4 days upon reaching ~80% confluence in the 75 cm2 culture flask. The cells were 




visually examined using the microscope (Axiovert 40 CFL; Zeiss, Jena). The ratio of sub-cultured 
cells transferred to the new culturing flask was 1:5. All the cell related work was done under the 
sterile bench. 
 
2.9.2 Thawing the cells 
The first steps in defrosting the cells should be performed as fast as possible to eliminate the 
DMSO from the freezing cells medium (90% FCS and 10% DMSO). For that, 10 ml from the pre-
warmed DMEM medium (with FCS and P/S) was transferred to 15 ml falcon tube. The Cryo tube 
(NuncTM Thermo Scientific, Schwerte) which contains the frozen cells was taken out from the 
liquid nitrogen tank (-170°C) and thawed by hand or in a 37°C water bath. Immediately when 
thawed, the cells were transferred to the 10 ml DMEM medium and centrifuged at 300 g and 
room temperature (Laborfuge 400R; Heraeus, Hanau). The supernatant was discarded and the 
cells were re-suspended in 5 ml DMEM medium (with FCS and P/S), then transferred to a 25 cm2 
flask. Further sub-culturing was done as described before. The cells were used for the 
experiments after the third passage to ensure they reach a stable vital condition. 
 
2.9.3 Counting the cells with Neubauer-cell chamber 
To count the HEK293 cells before sub-culturing them or plating them into the experimental 
plates, the old medium was discarded, then the cells were re-suspended in 10 ml DMEM (with 
FCS and P/S) and transferred to 50 ml falcon tube. 15 µl of the cell suspension was mixed (1:1) 
with 15 µl Trypan Blue (Sigma-Aldrich, Deisenhofen) by pipetting up and down. After mixing, 
15 µl of the staining mixture was transferred to the Neubauer-Cell Chamber which was covered 
with a cover slip. Cells’ concentration per ml was calculated using the following equation: 
 





Where 2 is coming from the 15 µl taken from the 30 µl staining mix (the dilution ratio), 4 is to 
have the average number of cells per one big square in the chamber and 104 is the glass factor. 
 




2.9.4 Transient transfection and luciferase reporter gene assay 
2.9.4.1 Generating the intron 3 polymorphism region (rs3857080) into pGL3-promoter vector 
(Luciferase reporter vector) 
pGL3-promoter vector was digested by the restriction enzymes KpnI and BglII [2.5.7.3]. Samples 
were run after each digestion on 0.8% agarose gel [2.5.5]. DNA was extracted from the gel by 
QiaCube® machine (Qiagen, Hilden) using the QIAquick Gel Extraction Kit (Qiagen, Hilden) 
[2.5.3]. Oligonucleotides were ordered to have compatible ends with the cutting sites of KpnI 
and BglII (Eurofins MWG Synthesis GmbH, Ebersberg) (Table 24). To ligate the oligonucleotides 
with the digested vector, the ratio 13:2 vector:oligonucleotide was used with 4 µl ligase buffer 
and 1 µl ligase enzyme (Ligate-ITTM Rapid Ligation Kit, USB, Staufen) [2.5.8]. Control was 
prepared in the last step with ddH2O instead of the inserted oligonucleotide. The ligation 
solutions got dialyzed [2.5.9] before the electroporation. Transforming the vector into the 
bacteria cells should be done after [2.8.4]. 
Bacteria were cultured overnight on solid agar containing ampicillin and then clones were 
picked for mini-prep [2.5.2.1] and sequenced to confirm the insertion [2.6.2]. Midi-prep [2.5.2.2] 
was performed to prepare more DNA from the successful clones and transfect those to the 
HEK293 cells [2.9.4]. 
2.9.4.2 Generating pcDNA3.1::LHX4 vector 
To assess the effects of the intron 3 polymorphism region on the luciferase assay with or 
without LHX4 protein, The same last HEK293 cells were transfected with pcDNA3.1 containing 
the open reading frame (ORF) of the transcription factor LHX4. The LHX4 was obtained from 
Source BioScience (Nottingham, UK) in pOTB7 vector. The LHX4-ORF was amplified by PCR using 
the modified oligonucleotides in Table 17 which included the restriction sites for HindIII and 
KpnI restriction enzymes. pcDNA3.1 (Invitrogen, Karlsruhe) was digested by the same restriction 
enzymes [2.5.7.3]. Ligation [2.5.8], dialysis [2.5.9] and the next steps were done as described 
previously. 
2.9.4.3 Luciferase assay (Reporter gene assay)  
HEK293 cells were cultured in DMEM medium containing 10% fetal bovine serum and 1% 
penicillin/streptomycin (100 u/ml and 100 µg/ml solved in distilled water respectively). In order 




to do the transfection, a total number of 3x105 cells/well was plated into each well of a twelve-
well plate. The wells were covered first with poly-D lysine and incubated at 37°C for 15 minutes, 
then the solution has been removed and the wells left to dry before plating the cells. A total 
amount of 0.8 µg/well of the DNA was transfected. When two vectors were transfected, the 
total DNA amount was 1.05 µg/well and divided like 3:1 (where 3 is for the pGL3-promoter and 
1 is for the expression vector pcDNA3.1 or pcDNA3.1::LHX4). FuGene6 (Roche, Mannheim) was 
used as transfection reagent (2.4 µl/well). The pCMV-Renilla-luciferase plasmid (1.7 ng/cm2) was 
used as an internal standard for transfection efficacy. The activity of the Firefly and Renilla 
reniformis luciferase reporter genes was assessed using the Dual-Luciferase Reporter Assay 
System (Promega, Manheim, Germany) according to the manufacturer instructions. Briefly, the 
cells were washed after 48 hours from transfection with 1X PBS, then lysed with 1X Passive Lysis 
Buffer (provided with the kit), then three cycles of freezing and thawing in liquid nitrogen. The 
samples were centrifuged at 13000 rpm for 5 minutes. The luciferase activity in the supernatant 
was measured by GloMax plate luminometer (Promega). 
 
 
Table 24: Oligonucleotides used in the different cloning procedures and luciferase assay 
Oligonucleotide sequence 
rs3857080 Major G-allele forward CAGAGAACTGAGTGTCGATTTTAATGTTTTTTTCa 
rs3857080 Major G-allele reverse gatctGAAAAAAACATTAAAATCGACACTCAGTTCTCTGgtac 
rs3857080 Minor A-allele forward CAGAGAACTGAGTGTCAATTTTAATGTTTTTTTCa 
rs3857080 Minor A-allele reverse gatctGAAAAAAACATTAAAATTGACACTCAGTTCTCTGgtac 
rs3857080 Minor A-allele forward Mutated CAGAGAACTGAGTGTCAGGGGTAATGTTTTTTTCa 
rs3857080 Minor A-allele reverse Mutated gatctGAAAAAAACATTACCCCTGACACTCAGTTCTCTGgtac 
 
 





2.10.1 Calculating the linkage disequilibrium using HaploView® v4.2 
2.10.1.1 From the two clinical studies 
The linkage disequilibrium of the polymorphisms within the studied volunteers of our two 
clinical studies was calculated and compared with the linkage disequilibrium from the 
genotyped population of the international HapMap project or 1000 genomes project. Two 
different files for the software should be prepared. The files’ extensions should be “.ped” and 
“.info” generated from a text tab-delimited files and have the exact same file name. the first 
“.ped” file has the first column for the subject ID, second is a serial number then four columns 
has the same values as the following “0, 0, 1, 0” which refer to “Family ID, individual ID, 
paternal ID, maternal ID” respectively. After the last six columns, the genotyped polymorphisms 
are placed in column in the same order in the “.info” file (Figure 13, part A). In the “.info” file, 
the polymorphisms IDs should be placed in vertical way (rows) with second column for their 
positions in the chromosome or as a relative position also (Figure 13, part B). The genotyped 
polymorphisms should be coded as the following: 0 as not determined, 1 for A, 2 for C, 3 for G 
and 4 for T with a space between each two numbers for the genotype (e.g. GC would be 3 2, 
Figure 13). The file could be opened using the first option from the open panel “Linkage 
format”. 
 
  Figure 13: Preparing the (.ped) and (.info) files for HaploView® v4.2 
(A) is an example of the (.ped) file. (B) is an example of the (.info) file. P1, P2, … are poylmorphism1, polymorphism2, … 
 
 




2.10.1.2 From the international HapMap Project 
Linkage data for genotyped polymorphisms from the international HapMap project could be 
downloaded directly from the software using “Download HapMap info track” command. The 
last option was not so useful because one could not choose the exact population. For that, the 
SNP genotype data file could be downloaded as “.txt” file from the website after choosing the 
required population http://hapmap.ncbi.nlm.nih.gov/cgi-perl/gbrowse/hapmap28_B36/, the 
file could be opened using the third option from the open panel “HapMap format”. 
2.10.1.3 From 1000 genomes project 
The detailed region information file was downloaded from the 1000 genomes project browser 
http://browser.1000genomes.org/index.html using their slicing tool for the exact position on 
the chromosome. The “.vcf” data file was opened by Microsoft excel and treated finally to get 
two separated files ready to be analyzed using HaploView software as described above 
[2.10.1.1]. 
 
2.10.2 Calculating the haplotypes using PHASE® v2.1 
The program PHASE® implements methods for calculating haplotypes from population 
genotype. The software also incorporates methods for predicting recombination rates. Phase 
program doesn’t have user interface (UI) and it needs to be run after preparing all the required 
files and placing them in one directory with the same path level on the PC. Four major steps 
have been done to prepare the data for further genotype phenotype analysis using SPSS® v20. 
As shown in Figure 14 (part A), genotyping data should be arranged first in a way that the 
polymorphisms are placed in column (P1, P2, P3….). All unavailable genotypes could be 
substituted with (?) sign. The f0 type of inputting the data file (.inp) was used (refer to the 
program manual for more file types), meaning two lines for each genotyped Individual (Figure 
14, part B). The first three lines of the input file should be on this exact order: 1st the number of 
individuals, 2nd the number of loci (genotyped polymorphisms) and 3rd the type of the entered 
polymorphism (e.g. SNP or Ins/Del). The results’ shape is shown in part C of Figure 14. The allele 
frequencies are calculated and the genotype for each participant is predicted. Finally, the file 
could be prepared in a way ready for statistical analysis by coding 0, 1 or 2 depending on the 
number of alleles for the exact haplotype which was predicted by the software (Figure 14, 




part D). To run the software after preparing the input file, one needs to edit multiple_seed.bad 




Figure 14: Calculating haplotypes using Phase® program v2.1 
 
2.10.3 Protein function prediction tools 
These tools were used to predict the effects of the non-synonymous SNPs on the coded protein 
functionality. The tools are using different algorithms to predict changed functionality. Most of 
them were trained upon known In Vitro proofed data. Some tools are predicting depending on 
the expected changes in the 3D structure of the protein, while other tools predict depending on 
the difference coming from the change in the alignments of the amino acids. The tools used in 









Table 25: Protein prediction tools 
Prediction tool Webpage 
PROVEAN (Protein Variation Effect Analyzer) v1.1.3 http://provean.jcvi.org/genome_submit.php 
SIFT (Sort Intolerant from Tolerant amino acid 
substitutions) v1.0.3 
http://provean.jcvi.org/genome_submit.php 
SNAP (Effects of single amino acid substitutions on 
protein function) (Bromberg and Rost, 2007) 
https://rostlab.org/services/snap/ 
PolyPhen-2 (PPH2) (Polymorphism Phenotyping v2) v2.2.2 http://genetics.bwh.harvard.edu/pph2/bgi.shtml 
nsSNPAnalyzer (predicting disease-associated non-
synonymous single nucleotide polymorphisms) 
http://snpanalyzer.uthsc.edu/ 
MutPred v1.2 (Li et al., 2009) http://mutpred.mutdb.org/ 
Mutation t@sting (Schwarz et al., 2010) http://www.mutationtaster.org/ 
PhD SNP (Predictor of human Deleterious Single 
Nucleotide Polymorphisms) 
http://snps.biofold.org/phd-snp/phd-snp.html 




2.10.4 Transcription factor prediction (TRANSFAC®) 
TRANSFAC® database 2013.1 was used to predict the possible transcript factors binding sites 
(Wingender, 2008) for the sequence around the region of the intron 3 polymorphism rs3857080 
in the aldosterone receptor gene NR3C2. The list was sorted to give the transcription factors 








3.1 Renal regulation candidate genes 
Earlier studies in the institute of clinical pharmacology have extensively searched for 
polymorphisms in the known renal ion transporter genes (e.g. SLC12A3 for the NCC, SLC12A1 for 
NKCC2, SCNN1A, SCNN1B and SCNN1G for the three ENaC subunits α, β and γ). Nevertheless, 
genomic variation in genes regulating expression or activity of these transporters had not yet 
been studied. By the systematic study of current literature, eleven possible candidate genes 
were identified to be scanned by predefined rules (see also Methods [2.3Selecting 
polymorphisms 2.3]): 6 coding kinases, one phosphatase, three co-transporters and the 
mineralocorticoid receptor gene (aldosterone receptor gene). Genes coding kinases were 
WNK1, WNK3, WNK4, STK39, OXSR1 and SGK1. The phosphatase gene was NEDD4L. The co-
transporters’ genes were KCNJ1, CLCKA and CLCNKB and the aldosterone receptor gene was 
NR3C2 (Table 26). 
 
Table 26: Renal regulation candidate genes 
Gene Protein Chr 
Nr. Of 
Exons 
Nr. Of Amino 
Acids 
Position on chromosome 
(GRCh37/hg19) 
Size [bp] 
WNK1 WNK1 12 28 2382 862089..1020618 158530 
WNK3 WNK3 X 24 1743 54219256..54384438 165183 
WNK4 WNK4 17 19 1243 40932649..40949084 16436 
STK39 SPAK 2 18 545 168810530..169104105 293576 
OXSR1 OSR1 3 18 527 38207026..38296979 89954 
SGK1 SGK1 6 17 431 134490384..134639196 148813 
NEDD4L NEDD4L 18 31 975 55711619..56068772 357154 
KCNJ1 ROMK 11 5 391 128707915..128737268 29354 
CLCKA ClC-Ka 1 20 687 16348486..16360545 12060 
CLCKB ClC-Kb 1 20 687 16370247..16383803 13557 






3.2 Selected and genotyped polymorphisms 
Applying the criteria for selecting polymorphisms in the candidate genes revealed 45 
polymorphisms to be genotyped (Table 27). Six polymorphisms out of the 45 selected ones 
could not be genotyped for technical reasons, because of the highly homologous regions where 
no specific primers could be designed. 39 polymorphisms were genotyped successfully. 31 SNPs 
out of the 39 genotyped polymorphisms in the 11 genes were polymorphic in our clinical 
studies’ participants. Randomly selected 20% of the samples were genotyped in duplicate with a 
100% match. 10% of the genotyped polymorphisms were checked for the possibility of typing 
errors by the technical assistant. 
For the exact numbers of the genotyped SNPs with the calculations of Hardy-Weinberg 
equilibrium using Chi square test (χ2) refer to supplementary materials [6.1.1]. 
 















rs3088353 WNK1 5’UTR 0 0.217 0.474 - 0.047 0.039 
rs2107614 WNK1 Intron 1 0 0.341 0.29 - - - 
rs765250 WNK1 Intron 1 0 0.345 0.295 - - - 
rs1159744 WNK1 Intron 2 0 0.258 0.238 - - - 





Intronic 0 0.142 0.109 Chr X Chr X Chr X 
rs3021280 WNK3 Intron 7 0 0.035 0.022 Chr X Chr X Chr X 
rs3021285 WNK3 Intron 11 0 0.067 0.092 Chr X Chr X Chr X 
rs3021284 WNK3 Intron 13 0 0.067 0.092 Chr X Chr X Chr X 
rs2516040 WNK3 Intron 22 0 0.15         
rs7880501 WNK3 3’UTR 0 0.048 0.022 Chr X Chr X Chr X 
rs74932519 WNK4 Promoter 0 0.181         
rs77879367 WNK4 Promoter 0 0.125 NP NP NP NP 
rs75596106 WNK4 Exon 2 
missense 
L [Leu]  ⇒ V [Val] 
Watson 0.5 NP NP NP NP 
rs78645838 WNK4 Intron 6 0 0.067 0.048 - - - 
rs61755606 WNK4 Intron 10 0 0.133 0.083 - - - 
rs77012584 WNK4 Intron 15 0 0.097 NP NP NP NP 



















rs1057293 SGK1 Exon 13 
synonymous 
D [Asp]  ⇒ D [Asp] 
0.098 0.122 - - - 
rs457661 OXSR1 Exon 1 
synonymous 
E [Glu]  ⇒ E [Glu] 
0.02 only in 
CEPH 
NP NP NP NP 
rs6599079 OXSR1 Exon 10 
missense 
T [Thr]  ⇒ I [Ile] 
0.117 0.105 - - - 
rs113919536 OXSR1 Exon 13 
missense 




NP NP NP NP 
rs35295772 OXSR1 Exon 14 
missense 
S [Ser]  ⇒ T [Thr] 




Q [Gln]  ⇒ Q [Gln] 0.358 0.334 0.012 - - 
rs2288774 NEDD4L Intron 6 0 0.491 0.467 - - - 
rs2846679 KCNJ1 Intron 2 0 0.133 0.14 - - - 
rs76640813 KCNJ1 Exon 5 
synonymous 
V [Val]  ⇒ V [Val] 
0.01 NP NP NP NP 
rs76937254 KCNJ1 Exon 5 
missense 
V [Val]  ⇒ A [Ala] 
Watson 0.5 NP NP NP NP 
rs10927887 CLCNKA Exon 4 
missense 
R [Arg]  ⇒ G [Gly] 
Watson is A/A 
Venter is G/G 
        
rs1010069 CLCNKA Intron 5 0 0.486 0.469 - - - 
rs1805152 CLCNKA Exon 14 
missense 
A [Ala]  ⇒ T [Thr] 
0.456         
rs12140311 CLCNKB Exon 15 
missense 
T [Thr]  ⇒ S [Ser] 
0.5 in 
Bushman 
        
rs2297727 CLCNKB Intron 17 0 0.45         
rs2070951 NR3C2 5’UTR 0 0.433 0.487 - - - 
rs5522 NR3C2 Exon 2 
missense 
V [Val]  ⇒ I [Ile] 
0.102 0.098 - - - 
rs10519963 NR3C2 Intron 2 0 0.15 0.135 - - - 
rs3846329 NR3C2 Intron 2 0 0.212 0.216 - - - 
rs3857080 NR3C2 Intron 3 0 0.115 0.111 - - - 
rs11099681 NR3C2 Intron 4 0 0.281 0.290 - - - 
rs11099680 NR3C2 Intron 4 0 0.292 0.288 - - - 
rs4835493 NR3C2 Intron 4 0 0.281 0.286 - - - 
rs6810951 NR3C2 Intron 4 0 0.408 0.389 - - - 
rs1040288 NR3C2 Intron 6 0 0.434 0.426 - - - 
rs11737660 NR3C2 Intron 8 0 0.212 0.236 - - - 
rs5534 NR3C2 3’UTR 0 0.42 0.410 0.034 - - 
Marked polymorphisms could not be genotyped for technical reasons. MAF minor allele frequency. dbSNP 137 Single Nucleotides 
Polymorphisms database build version 137. HWE is referring to Chi square test (χ2) for Hardy-Weinberg disequilibrium. Study 1 
and 2 are the clinical study 1 on loop diuretics and clinical study 2 on hydrochlorothiazide and triamterene. NP was not 







3.3 Selecting genes for further investigations 
The repetitive analyze of covariance has been done in three statistical models [2.4.1]. The first 
statistical model included the excretion on the diuretic drugs as covariate, the second included 
all the previously known affecting polymorphisms and the third didn’t include any other than 
the studied polymorphism. The model of our interest was always the first statistical model 
which has the excretion of the diuretic drug into consideration as covariate only. First analysis 
has been done for all polymorphic polymorphisms (Table 28). The two clinical studies were 
divided to be analyzed depending on the diuretics’ mechanism of action. 
As documented in Table 28, under monovariate statistics not taking multiple testing into 
account, a number of polymorphisms were associated with the relevant phenotypes. However, 
when focusing on the most significant associations, the polymorphisms in aldosterone receptor 
appeared most promising. As illustrated by the color highlighting, the polymorphisms and 
haplotypes in the aldosterone receptor gene were significantly associated with numerous 
phenotypes. The p-values were rather small for number of associations in different genes, 
although by strict adjustment for multiple testing, where p-value should be less than 0.0001, the 






Table 28: P-values from repetitive analyze of covariance (RANCOVA) of studied polymorphisms and haplotypes 
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rs3088353 T > G 
    
- - 
 
- -  - - 
 
47% 5’UTR 
rs2107614 G > A 
    
- .010 
 
- -  - - 
 
29% Intron 1 
rs765250 A > G 
    
- .024 
 
- -  - - 
 
30% Intron 1 
rs1159744 C > G 
    
- .007 
 
- -  - - 
 
24% Intron 2 
rs2277869 T > C 
    
- .040 
 
- -  - - 
 
18% Intron 26 
H1_1 
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WNK3 
                  
rs3021280 G > T 
    
- -  - -  - - 
 
2% Intron 7 
rs3021285 T > C 
    
.065 - 
 
.026 -  - - 
 
9% Intron 11 
rs3021284 A > T 
    
.065 - 
 
.026 -  - - 
 
9% Intron 13 
rs7880501 T > C 
    
- - 
 
- -  - - 
 
2% 3’UTR 
rs2495801 C > T 
    
.034 - 
 


































                   
WNK4 
                  
rs78645838 G > A 
    
- .014 
 
- -  - - 
 
5% Intron 6 
rs61755606 G > A 
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NEDD4L 
       
 
  
     
   
rs4149601 C > T 
    
- - 
 
- -  - - 
 
33% 5’UTR Exon 1 
rs2288774 A > G 
    
- .038 
 
- -  - - 
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STK39 (SPAK) 
                  
rs35929607 A > G 
    
.041 - 
 
.012 -  - .075 
 





                   
OXSR1 (OSR1) 
                  
rs6599079 G > A 
    
- -  - -  - - 
 
11% Exon 10 
                   
SGK1 
                  
rs9493857 C > T 
    
- -  - -  - - 
 
19% Intron 2 
rs3215438 - > G 







45% Intron 5 
rs1743966 T > C 
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CLCNKa 
                  
rs1010069 G > A 
    
- .024 
 
.086 -  - - 
 
47% Intron 5 
                   
KCNJ1 (ROMK) 
                  
rs2846679 C > T 







14% Intron 2 
                   
NR3C2 (aldosterone receptor) 
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P<0.1 yellow. P<0.05 red cells. P<0.01 red cells with bold black font. BFT loop diuretics study days from clinical study 1. HCT 
hydrochlorothiazide study days from the clinical study 2. TRIA triamterene study day from the clinical study 2. Nucleotides in grey 
are the minor alleles. UTR untranslated region. The (e) prefix in the haplotype functional localization is for exons. The (i) prefix in 
the haplotype functional localization is for introns. Haplotypes are named as Haplotype number_allele number. NaCl is the 
association with sodium and chloride excretion as composite endpoint. K is the association with potassium excretion. All the 
association of NaCl and K excretion in this table were for the time between 0 and 24 hours. (-) refers to no significance. (N) was 
for two SNPs in the SGK1 gene which were only genotyped in the first clinical study. The statistical model included the diuretic 






3.4 Aldosterone receptor polymorphisms 
3.4.1 Phenotype-genotype association 
Twelve polymorphisms in the aldosterone receptor gene (NR3C2) in both clinical studies were 
investigated. 229 participants of the two clinical studies were genotyped for twelve NR3C2 
polymorphisms formerly identified to be associated with clinical phenotypes (Table 3).  
Urinary ion excretion was associated mainly with only one of the twelve polymorphisms, the 
intron-3 polymorphism (rs3857080). The significance of the genotype-phenotype associations 
for the 12 studied polymorphisms and calculated haplotypes are presented in Table 29. 
3.4.2 Linkage disequilibrium 
The linkage disequilibrium among the polymorphisms was similar in our population from both 
clinical studies and in the Caucasian chromosomes of the 1000-Genomes project 
(www.1000genomes.org/) (Figure 15). The SNP found in our study to be significantly associated 
with renal salt handling (rs3857080) was between two major linkage blocks and not linked more 
than 36% on a range of 180 kb right and left with any other polymorphisms. Calculating 
haplotype-phenotype associations did not give additional information over polymorphism-










             




             
NaCl K    NaCl K    NaCl K      
  
major > minor 
 
                




rs2070951   G > C                     .030 -   - -   - -  49% 5’UTR 
rs5522   A > G                     .062 -   - -   .051 .024   10% Exon 2 
rs10519963   C > T                     - -   - -  - -   14% Intron 2 
rs3846329   C > A                     - -   .011 -  - -   22% Intron 2 
rs3857080   G > A                     .000 .067   - .004   - .026   11% Intron 3 
rs11099681   T > C                     .023 .092   - -   - -   29% Intron 4 
rs11099680   T > C                     .023 .092   - -   - -   29% Intron 4 
rs4835493   G > A                     .036 -   - -   - -   29% Intron 4 
rs6810951   C > A                     .092 .001   - .068   - -   39% Intron 4 
rs1040288   C > G                     - .044   - -   - -   43% Intron 6 
rs11737660   G > A                     .075 -  - -   - -   24% Intron 8 
rs5534   C > T                     - -  - -   - -   41% 3’UTR 
                                                    
Haplotypes   
                      
 
    
H1_1   C A                       .030 -  - -   - -   49% 5’UTR_e2 
H1_2   G A                       - -  - -   - -   41% 
 H1_3   G G                       .062 -  - -   .051 .024   10% 
 
 
                            - -       
 
 
 H2_1       C C                   - -   .010 -   - -   75% i2 
H2_2       C A                   - .088   .069 -   - -   11% 
 H2_3       T A                   - -   - -   - -   10% 
 H2_4       T C                   - -   - -   - .077   3% 
 
 
                              
 
     
 
 
 H3_1             T T G C C G T   - -   - -   - -   26% i4_3’UTR 
H3_2             C C A C G G C   - -   .082 -   - -   11% 
 H3_3             T T G A C A C   .048 .019   - .025   - -   11% 
 H3_4             T T G A G G C   .091 -   - -   - -   10% 
 H3_5             T T G A C G C   .024 -   - -   - -   10% 
 H3_6             C C A C G G T   .052 -   - -   - -   8% 
 H3_7             C C A C G A C   - -   - -   - -   7% 
 H3_8             T T G A C G T   - -   - -   - -   5% 
 H3_9             T T G C C G C   - .083   .006 -   .061 -   3% 
 H3_10             C C A A C A C   .088 -   - -   - -   2% 
 H3_11             T T G C G G T   - .001   .036 -   .061 -   2% 
 H3_12             T T G C G A C   - -   .017 -   .020 -   2% 
 H3_13             T T G C G G C   - -   - -   .071 -   1% 
 H3_14             T T G C C A C   - -   - -   - -   1% 
 H3_15             T T G A G A C   - -   - .002   - -   1% 
 P<0.1 yellow. P<0.05 red cells. P<0.01 red cells with bold black font. BFT loop diuretics study days from clinical study 1. HCT 
hydrochlorothiazide study days from the clinical study 2. TRIA triamterene study day from the clinical study 2. Nucleotides in grey 
are the minor alleles. UTR untranslated region. The (e) prefix in the haplotype functional localization is for (exon). The (i) prefix in 
the haplotype functional localization is for (intron). Haplotypes are named as Haplotype number_allele number. NaCl is the 
association with sodium and chloride excretion as composite endpoint. K is the association with potassium excretion. All the 
association of NaCl and K excretion in this table were for the time between 0 and 24 hours. (-) refers to no significance. The 









 Figure 15: Linkage disequilibrium among the investigated polymorphisms 
 
The figure depicts the linkage disequilibrium among the investigated polymorphisms. The upper part depicts the approximate 
position of the polymorphisms in relation to the exon-intron structure of the aldosterone receptor gene and the linkage 
disequilibrium in the pooled two populations of our two clinical studies (“This population”). The lower part depicts the linkage 
disequilibrium in the Caucasian chromosomes of the 1000-genomes project (www.1000genomes.org/). The darker the shading of 
the diamonds, the stronger the linkage disequilibrium; the numbers in the diamonds (in the upper part) are the respective r2-
values. The three big black triangles in both parts demark the three corresponding linkage disequilibrium blocks (also called 






3.4.3 Effects on sodium and chloride excretion and potassium excretion 
Higher sodium and chloride excretion after bumetanide and furosemide, and higher potassium 
excretion under most circumstances were associated with minor A-allele of rs3857080 (Figure 
16, Figure 17, Table 30). Sodium and chloride excretion was evaluated as a combined endpoint 
(Na&Cl). Single regression analyses without further predictors in the model revealed near three 
gram higher sodium&chloride excretion over 24 h per A-allele after bumetanide or furosemide 
(Table 30) corresponding to about five to six gram higher sodium&chloride excretion per day in 
carriers of two A-alleles compared to two G-alleles. Five to six grams were one fourth of the 
mean sodium&chloride excretion after bumetanide or furosemide (Table 30). 
Higher potassium excretion was associated with the minor A-allele under most conditions 
(Figure 16, Figure 17 and Table 30). Regression analyses without adjustment revealed about half 
a gram higher potassium excretion over 24 h per A-allele under these circumstances (Table 30). 
Volume excretion was associated with rs3857080 similar to potassium but statistically weaker. 
The statistical model was extended to test the stability of the associations (compare Figure 17 
with Table 30). The excreted drug amounts and the eight polymorphisms earlier reported to be 
implicated with urinary electrolyte excretion in the study populations were stepwise included  
(Vormfelde and Brockmoller, 2012; Vormfelde et al., 2006; Vormfelde et al., 2007; Vormfelde et 
al., 2010). The above mentioned associations, especially the effect sizes, remained stable.  
Torsemide is a loop diuretic similar to bumetanide and furosemide, nonetheless torsemide 
additionally blocks the aldosterone receptor, and this difference is highly relevant to the 
interpretation of our study. The complete pattern of associations after torsemide appeared 
different from those after bumetanide and furosemide (Figure 17, Table 30). Furosemide 
appeared similar to bumetanide rather than to torsemide in terms of comparable effects’ sizes 
with potassium and similar associations with sodium plus chloride and volume excretion (Figure 
17, Table 30). Calculating the phenotype-genotype associations separately for intervals of 0-6 h 












  Figure 16: Sodium and Chloride, and potassium excretion by rs3857080 genotypes 
The figure depicts the 24 h excretion of Sodium and chloride (Na&Cl) after furosemide intake (left) and of potassium on moderate 
sodium chloride restriction (right) in relation to the genotype of rs3857080. Sodium and chloride excretion was evaluated as a 
combined endpoint Na&Cl. Data are mean/SEM. Symbol sizes are proportional to the group sizes. Number of participants in the 
genotypic groups are GG:72, GA:19, AA:1 for Na&Cl after furosemide, and GG:76, GA:23, AA:0 for potassium on moderate 
sodium chloride restriction. Concerning this polymorphism (rs3857080), there was 87, 22 and 1 carriers of the GG, GA and AA 
genotypes in the first study and 93, 25 and 1 carriers of GG, GA and AA in the second study (the AA carrier in the second study did 







Figure 17: Differences in urinary sodium&chloride, and potassium excretion with rs3857080 and Ile180Val (rs5522) 
The figure depicts the mean differences in the 24 h excretion of sodium and chloride (Na&Cl) and of potassium (K+) associated 
with the two polymorphisms rs3857080 and Ile180Val (rs5522). Data are mean differences (±SEM). Predictors included in the 
statistical model were the two NR3C2 polymorphisms, urinary drug excretion and the eight polymorphisms formerly published to 
affect urinary excretion in our studies (Vormfelde and Brockmoller, 2012; Vormfelde et al., 2006; Vormfelde et al., 2007; 
Vormfelde et al., 2010) (for more details see paragraph [2.4.1] in the methods for the second statistical model). Data are 
presented per two alleles for two reasons: To reflect the natural bi-allelic situation and to allow sensible comparison with cohort 
means. Numbers give the differences associated with two minor alleles (A- or valine-alleles) compared to two major alleles (G- or 







Figure 18: Time course of potassium and sodium&chloride excretion by rs3857080 genotype 
The figure depicts the electrolyte excretion over 24 h separately for homozygous G-allele carriers of rs3857080 (grey diamonds) 
and heterozygous G/A-carriers (black diamonds). The figure depicts the time courses of sodium and chloride excretion (Na&Cl) 
after furosemide in part A and the time course of potassium (K+) excretion after 100 mg hydrochlorothiazide in part B, after 
triamterene in part C, and after moderate sodium chloride restriction in part D. Data are given as means and SEM. Symbols sizes 
are proportional to the genotyped numbers. Repeated measures analysis of variance with time as within- participants variable 
and rs3857080 genotype as the between-participants factor has been performed. Differences between the genotypes were 








Table 30: Mean urinary 24 h excretion and differences in 24 h excretion of volume and electrolytes in relation to rs3857080 and 
Ile180Val 
     Study 1  Study 2 
     Bumetanide Furosemide Torsemide     HCT 25 mg a HCT 100 mg Triamterene NaCl-restriction b 
Volume (l/d) c  4.9±0.2 4.9±0.2 4.5±0.2  3.5±0.1 3.8±0.1 3.0±0.1 3.0±0.1 
 rs3857080 d  0.5±0.8 0.5±0.8 -0.2±0.7  1.2±0.6 * 0.8±0.6 1.5±0.6 * 0.7±0.3 * 
 Ile180Val d  -0.9±0.9 -1.8±0.9 * -0.9±0.9  0.5±0.6 0.3±0.6 0.3±0.6 -0.2±0.3 
Na&Cl (g/d) e  21.5±0.4 21.3±0.5 17.4±0.4  12.8±0.5 17.9±0.5 8.7±0.4 7.7±0.2 
 rs3857080  4.7±2.0 * 6.2±2.0 ** 1.7±1.7  -0.7±2.4 0.3±2.4 -0.3±1.9 0.4±1.0 
 Ile180Val  -3.6±2.4 -2.7±2.4 -1.9±2.0  2.3±2.3 0.4±2.3 3.7±1.7 * 0.5±0.9 
K+ (g/d)  2.9±0.1 3.1±0.1 2.6±0.1  3.8±0.1 4.3±0.1 2.3±0.1 2.9±0.1 
 rs3857080  0.7±0.3 * 0.4±0.3 -0.1±0.3  1.1±0.6 (*) 1.3±0.6 * 1.1±0.5 * 0.9±0.3 ** 
 Ile180Val  -0.3±0.4 -0.7±0.4 (*) -0.2±0.4  1.0 ±0.6 0.6±0.6 1.0±0.4 * 0.5±0.3 * 
 
a HCT = Hydrochlorothiazide. 
b NaCl-restriction = moderate sodium chloride restriction (mean 7.7±3.4, 7.3±3.3 and 8.0±3.4 g per 24 h on the three 
placebo days before 25 mg HCT, 100 mg HCT and triamterene, respectively) 
c data are mean±SEM of the entire study cohort 
d data are mean differences (±SEM). They were calculated with single linear regression analyses with no further 
potential predictor included in the model. Data are presented per two alleles to reflect the natural biallelic situation, which is also 
the basis for the means of the entire study cohort. Numbers give the differences associated with two minor alleles (A- or valine-
alleles) compared to two major alleles (G- or isoleucine-alleles). 
e Na&Cl = sodium&chloride as composite endpoint 
(*), *, ** (*) indicates p=0.1-0.05, * indicates p<0.05, and ** indicates p<0.01 as p-values from single linear regression analyses 













3.4.4 Comparing the effects of the polymorphisms with the pharmacokinetic effects 
Large fractions of variation were attributed to rs3857080 (Figure 4). rs3857080 explained 
relevant percentages of variation in sodium and chloride excretion after bumetanide and 
furosemide and in potassium excretion after most conditions (Figure 19). Taken together, the 
ten investigated polymorphisms (eight previously and two from NR3C2) explained 34.2% in the 
urinary sodium and chloride excretion after bumetanide or furosemide and 23.2%, 19.3% and 
11.0% in the urinary potassium excretion after hydrochlorothiazide, after triamterene and on 
moderate sodium chloride restriction, respectively. These fractions were larger than those 
explained by the respective urinary drug excretion. As Figure 19 shows, rs3857080 explained 












Figure 19: Variation in 24 h electrolyte excretion explained by ten genetic polymorphisms and urinary drug excretion 
The figure depicts the fractions of the variation in urinary electrolyte excretion, which were attributed to ten genetic 
polymorphisms and to urinary drug excretion. Shown are the fractions of variation in the 24 h excretion of sodium plus chloride 
(Na&Cl) after bumetanide and furosemide in part A and of potassium (K+) after 25 mg and 100 mg hydrochlorothiazide (HCT) in 
part B, after triamterene in part C and after moderate sodium chloride restriction in part D. Data are from four covariance 
analyses. We analyzed the bumetanide and the furosemide study days together and the two hydrochlorothiazide study days (HCT 
25 and 100 mg) also together. 
Predictors included in the model besides urinary drug excretion were as follows: ACE I/D, the insertion/deletion polymorphism 
rs1799752 in the angiotensin I-converting enzyme; ADD1 Gly460Trp (also referred to as rs4961) in alpha-adducin; GNB3 C825T 
(rs5443) in the G protein subunit beta 3; ANP Val32Met (rs5063) in the atrial natriuretic peptide precursor; ANP Ter152Arg 
(rs5065), which is a termination to arginine exchange; NCC Gly264Ala (rs1529927) in the sodium-chloride cotransporters; ENaC-ß 
H2_1, a frequent haplotype in the beta subunit of the epithelial sodium channels composed by the T, C and A alleles of rs152728, 
rs238547 and rs152745 (Vormfelde et al., 2007); ENaC-g Leu649Leu (rs5723) in the gamma subunit of the epithelial sodium 
channel; NR3C2 rs3857080, the intron 3 polymorphism in the aldosterone receptor gene and NR3C2 Ile180Leu (rs5522) in the 
aldosterone receptor gene. 
Bumetanide and furosemide excretion explained 12.7% of the variation in sodium plus chloride excretion after their intake in a 
common analysis (part D). In that analysis, NR3C2 rs3857080 explained 10.1% (p<0.001) and NR3C2 Ile180Leu explained 2.0% 
(p=0.069). 
After hydrochlorothiazide (part B, 25 mg and 100 mg analyzed together), urinary hydrochlorothiazide excretion explained 16.3% 
of the variation in potassium excretion (p<0.001), NR3C2 rs3857080 explained 6.2% (p<0.001), NR3C2 Ile180Val was negligible 
(0.1%). 
Urinary triamterene excretion explained 3.4% (p=0.086) of the variation in potassium excretion after triamterene (part C) 
compared to NR3C2 rs3857080: 6.9% (p=0.014). 
The most considerable predictor of the variation in potassium excretion during moderate sodium chloride restriction (part D) was 






Among all other aldosterone receptor polymorphisms studied, only the Ile180Val polymorphism 
appeared to be functionally relevant. Potassium and sodium&chloride excretion were weaker 
associated with the polymorphism Ile180Val (rs5522) with and without controlling for drug 
excretion and other polymorphisms (Figure 17, Table 30). After triamterene, the size of the 
differences was comparable to those observed with rs3857080 with one gram potassium and 
four gram sodium and chloride on the study day (Figure 17). The pattern of associations with 
Ile180Val differed from that with rs3857080 but both were also not genetically linked at all 
(Figure 15). 
 
3.5 Functional study of the intron 3 polymorphism (rs3857080) in the aldosterone 
receptor gene (NR3C2) 
The A-allele of rs3857080 does not change protein structure but may enhance the binding of 
transcription factors. For that the Electrophoretic mobility shift assay (EMSA) was performed 
first to detect any DNA-protein binding possibility before going further into the investigation of 
the intronic polymorphism. 
3.5.1 DNA-protein binding (EMSA) 
In electrophoretic mobility shift assay (EMSA), several types of evidence indicated that the 
intron 3 polymorphism (rs3857080) affects transcription factor binding. The region around the 
polymorphism showed strong nuclear protein binding (Figure 21 B, lane 2). Both major and 
minor alleles had shown DNA-protein binding bands with more intense second band for the 
minor-A allele of rs3857050. A possible negative control was selected from the set of already 
genotyped SNP as a self-testing for the statistical analysis. The negative control was selected to 
be an intronic SNP also from the same aldosterone receptor gene NR3C2 which showed no 
significant association to the studied phenotypes (rs11099680). The positive control was cAMP-





Figure 20: Electrophoretic mobility shift assay for minor-A and 












Nuclear cell extract was from the HEK293 cells. Negative 
control (rs11099680) was selected from the genotyped SNPs in 
the aldosterone receptor gene with no significance. Positive 
















Electrophoretic mobility shift assay shows the 
binding of nuclear protein extracts of HEK293 cells to 
the rs3857080 DNA region. (A) Sequence of the 
minor A-allele of rs3857080. Underlined are the four 
mutated nucleotides of the minor A-allele. The 
sequence of the LHX4 consensus shows the binding 
site (underlined) (Machinis and Amselem, 2005) with 
the expected weight matrix created with 
WebLogo 3.3 using the position dependent 
probabilities from TRANSFAC® (This analysis was 
kindly provided by Mr. Martin Haubrock, 
department of bioinformatics, Göttingen University). 
(B) Radioactive probe was always the 
oligonucleotide of the minor-A-allele of rs3857080 
DNA region (Table 22). Two bands were always 
detected by this binding. The cold competition shows 
allele-specific differences in DNA-protein binding 
between the major-G- and minor-A-allele. The 
unlabeled cold competitors were given in 10X- to 
50X-fold molar excess of the labeled probe. The use 
of the anti-LHX4 antibody resulted in reduction of 
the signal compared to the IgG as a control. (C) 
Quantification of the cold competition signals for the 
lower band from five independent experiments 
(mean±SEM). There was significant difference in 
relation to the type of cold competitor or in relation 
to how many folds molar excess were used (p<0.01). 
Significances were calculated using two-way ANOVA 
(SigmaPlot 11.0) taking into consideration the type 






Figure 21: Electrophoretic Mobility Shift Assay for 






3.5.1.1 Allele specific binding (Cold competition) 
The binding of the nuclear proteins was stronger with the minor A-allele compared to the G-
allele (Figure 21 B, lanes 3 to 8), a difference, which was statistically significant  [p<0.001 (lower 
band)], (Figure 21 C).  
3.5.1.2 Transcription factors prediction using TRANSFAC® 
Bioinformatics analysis suggested a list of possible transcription factors that might bind to the 
region of rs3857080 [for the complete list and details see the supplementary materials 6.1.2]. 
The list was sorted from the higher hit numbers to the lower (Supplementary table 4). The 
transcription factors with higher hit numbers in the WT-frequency column than the Variant-
frequency column were excluded from being tested. The corresponding consensus for the 
tested transcription factors are presented in Table 31. 
 
Table 31: consensus for the seven tested transcription factors 
Protein 
Name 
Consensus Source (citation) 
Msx1 ATCCATTGCACACTAATTGGAGGCTGTAG (Catron et al., 1993) 
Sox4 AGACTGAGAACAAAGCGCTCTCACAC 











(Ghosh et al., 2001) 






Two possible relevant transcription factors were identified. Among the 7 most promising 
candidates suggested by bioinformatics analysis, we identified the transcription factor LHX4 and 
Barx1 to bind to the rs3857080 region. Cold competition with unlabeled LHX4 and Barx1 














Cold competition with the consensus of predicted 
transcription factors by the TRANSFAC database. The 
nuclear extract was from HEK293 cells. The radioactive 
probe was always the labeled minor-A allele of 
rs3857080. The mole excess of the unlabeled probes 
ranged between 10X to 30X. Both LHX4 and Barx1 could 
compete with the labeled probe to eliminate the second 








Aligning the sequences for the rs3857080 region with the LHX4 and Barx1 used consensus 
revealed into shared binding core between all (Figure 23, blue cells).  
rs3857080_major allele g a t c C A G A G A A C T G A G T G T C G A T T T T A A T G T T T T T T T C 
rs3857080_minor allele g a t c C A G A G A A C T G A G T G T C A A T T T T A A T G T T T T T T T C 
                                       
rs3857080_major_compl g a t c G A A A A A A A C A T T A A A A T C G A C A C T C A G T T C T C T G 
rs3857080_minor_compl g a t c G A A A A A A A C A T T A A A A T T G A C A C T C A G T T C T C T G 
LHX4 G T A T G A G T A T G A A T C A T T A A T T G A C A A C A T A T 
      
Barx1 
             
A A A G T A A T T G A C A C A T 
         
 
Figure 23: Aligned sequences of the rs3857080 region with LHX4 and Barx1 consensus. 
rs3857080 polymorphism in red. Blue barked nucleotides are the shared region between all. Compl referes to the complimentary 






3.5.1.3 Super shift assay – determining the predicted transcription factor 
The Anti-LHX4 antibody clearly reduced the intensity of both bands (Figure 21 B, lanes 9 and 
10). While the Anti Barx1 didn’t affect the binding affinity to the labeled probe of the minor-A 
allele of the rs3857080 polymorphism. 
3.5.1.4 Mutating the possible binding site 
As one more step of confirming the specificity of LHX4 binding to the rs3857080 region, four 
nucleotides in the LHX4 consensus oligonucleotide were mutated as in (Machinis and Amselem, 
2005) and in the same corresponding nucleotides in the minor A-allele oligonucleotide. EMSA 































Mutating four nucleotides in the expected binding core for the 
minor-A allele of rs3857080 and LHX4 consensus revealed into 





















3.5.2 Reporter gene assay 
3.5.2.1 Generating plasmids with the major-G-, minor-A-, and minor-mutated –alleles 
Three different plasmids were generated, each of them from two different clones. All plasmids 
contained the rs3857080 region inserted before both the promoter and the firefly luciferase 
sequences (Figure 25). The first plasmid contains the major-G allele of the rs3857080, the 
second contains the minor-A allele and the third contains the same mutated allele of rs3857080 
which was used in the EMSA experiments. The insertion was done by using the restriction 
enzymes KpnI and BglII [2.9.4.1]. 
 
 









3.5.2.2 Effects of the constructs on luciferase assay 
The previous plasmids with the major-G, minor-A and mutated alleles were transfected into 
HEK293 cells. The pCMV-Renilla-luciferase plasmid was transfected also into the same HEK293 
cells for normalization as an internal standard. Luciferase assay was performed as described in 
[method 2.9.4.3]. The results for each construct are coming from two different clones with more 
than three repetitions. The average of the firefly luciferase activity was calculated after 
normalizing the measurements to the renilla luciferase acitivity (Figure 26). The activity 
increased by almost 1.7 folds for the three transfected clones. 
 
  Figure 26: Reporter gene assay for the rs3857080 major-G, minor-A and mutated alleles 
The figure depicts the firefly luciferase activity after normalizing the measurements to the renilla luciferase activity. The figure 






3.5.2.3 Generating expression plasmid with LHX4 (pCDNA3.1::LHX4) 
The possible coding sequence for the LHX4 protein was delivered in pOTB7 vector. The pOTB7 
vector is not an expression vector, for that it was necessary to re-clone the open reading frame 
(ORF) of the LHX4 into an expression vector (e.g. pcDNA3.1). First, the sequence of the LHX4 in 
the pOTB7 vector was checked by sequencing one of the selected clones using 7 primers to 
cover the whole sequence (Table 17). The sequencing was done to check if there is any 
mutation that might cause a stop codon in the LHX4 sequence. After proofing the correct 
sequence, the LHX4-ORF was amplified using two designed primers with a specific restriction 
enzyme sites included (Table 10). The restriction enzymes were HindIII and KpnI. pcDNA3.1 was 
double digested using the same restriction enzymes for end compatibility before ligation. The 




  Figure 27: re-cloning LHX4-ORF from pOTB7 into pcDNA3.1 vector. 
The figure depicts the general performed steps to re-clone the LHX4-ORF from the non-expression vector pOTB7 into the 






3.5.2.4 Effects of the constructs on luciferase assay when LHX4 is expressed 
The same reporter gene assay experiments were repeated in the presence or absence of the 
LHX4. Firefly luciferase showed higher activity in the presence of LHX4 in the all constructs with 
a little less activity with the mutated allele of the rs3857080 (Figure 28) 
 
Figure 28:  Reporter gene assay for the rs3857080 major-G, minor-A and mutated alleles in the presence or absence of LHX4 
The figure depicts the firefly luciferase activity after normalizing the measurements to the renilla luciferase activity. The figure 
shows the increased fold activity in comparison to the empty transfected vector in the presence or absence of the LHX4. Data are 








3.6 WNK4 results 
3.6.1 Pooling the samples 
Samples from each clinical study were divided into two groups. The criterion was sodium and 
chloride excretion between 0 and 24 hours (NaCl_0_24). The used phenotype was adjusted for 
the creatinine clearance first as explained in the methods [2.2.3]. The DNA concentration of the 
samples was measured using the PicoGreen® assay [2.5.6.2], then normalized by Qiagility® 
pipetting machine to 10 ng of DNA per sample. Table 32 Shows the four different groups with 
the corresponding barcodes which were used in the next generation sequencing: 
 
Table 32: Pooled DNA samples into four different groups from two clinical studies 
Clinical Study Term Phenotype Nr. Samples Barcode for sequencing 
Loop diuretics study Diu1_1 High sodium and chloride excreters 47 7 
Diu1_2 Low sodium and chloride excreters 48 8 
Hydrochlorothiazide and 
Triamterene study 
Diu2_1 High sodium and chloride excreters 51 9 
Diu2_2 Low sodium and chloride excreters 52 10 
 
3.6.2 Confirming and validating the detected polymorphisms 
Many parameters could affect the detected polymorphisms by the bioinformatics tools. The 
coverage was one of the most interesting parameters that should be adjusted in addition to the 
allele frequency (number of reads). With 100X coverage of the exon regions of WNK4 gene, 
there were 163 detected possible polymorphisms. The list was further filtered by choosing 
polymorphisms that had more than 0.7% minor allele frequency (almost one read per 100, 
meaning almost one read per divided groups). The list was reduced to 126 polymorphisms. 
Choosing the non-synonymous SNPs only reduced the number of polymorphisms to 69 SNPs. As 
the technique is known of its false positive detection of polymorphisms when they are in 
homopolymere region, all polymorphisms within such regions were sorted out manually. Finally, 
25 possible non-synonymous SNPs were validated further by genotyping using SNaPShot® 
[2.6.1] or capillary sequencing [2.6.2]. There were only five true SNPs out of the validated 






Table 33: Detected and validated SNPs in the WNK4 gene 
Amino acid change 
Position 
(GRCh37/hg19) 
Ref allele Alt allele dbSNP 137 Genotypes MAF 
S239W 40934873 C G NOVEL 1 Het* pool 9 DIU2_1 0.009 
V358A 40936500 T C NOVEL 
1 Het Pool 8 DIU1_2 
1 Het Pool 10 DIU2_2 
0.01 
P1025L 40947694 C T rs56099549 
3 Het Pool 7 DIU1_1 
1 Het Pool 9 DIU2_1 
2 Het Pool 10 DIU2_2 
0.01 
V1084A 40947871 T C rs148648427 1 Het Pool 7 DIU1_1 0.01 
R1204C 40948319 C T rs56116165 1 Het pool 10 DIU2_2 0.009 
* Het refers to heterozygous. S serine, W tryptophan, V valine, A alanine, P proline, L leucine, R arginine and C cysteine. 
 
The five SNPs were applied for nine protein prediction tools [2.10.3]. One of the two novel 
validated SNPs was predicted to be deleterious by all protein prediction tools. The final results 
of the five detected and validated SNPs with the functional predictions on the protein function 
are presented in Table 34. The used primers in validating the five SNPs are presented in 
Supplementary materials [6.1.4]. 
 
Table 34: protein function predictions for the five validated polymorphisms in the WNK4 gene 
Amino acid change dbSNP 137 PROVEAN SIFT SNAP PPH2 nsSNPAnalyzer MutPred Mutation t@sting PhD SNP SNPs&Go No.D 
S239W NOVEL D D D D D D D n D 8 
V358A NOVEL D D D D D D D D D 9 
P1025L rs56099549 D D n D D n D n n 5 
V1084A rs148648427 n n n n D n n n n 1 
R1204C rs56116165 D D D D D n D n n 6 








The analyses are based on two clinical studies. In the first clinical study, we studied the effects 
of three loop diuretic drugs in about 100 healthy volunteers. In the second clinical study, we 
studied the effects of moderate sodium restriction, hydrochlorothiazide and triamterene in 
about 100 volunteers also. The purpose of this pharmacogenomics study was to identify 
inherited polymorphisms which had an impact on renal handling of salt and water excretion. 
The healthy volunteers were genotyped systematically for 39 polymorphisms in 11 genes 
responsible for regulation of the activity of renal salt transporters. During the analysis, two 
genes arose as candidates for further investigation, the mineralocorticoid receptor gene NR3C2 
and the with-no-lysine 4 kinase gene WNK4. The NR3C2 gene arose as a most promising 
candidate gene since the intron 3 polymorphism (rs3857080) in that gene was of high impact 
mostly on potassium excretion under most conditions in both clinical studies. In silico and in 
vitro studies showed that the intron 3 polymorphism region has a possible binding site with the 
LHX4 transcription factor which was confirmed to some extent by in vitro cell biology studies. 
The WNK4 gene got into our special focus, because on one hand it is considered relevant for 
several functions and diseases but on the other hand in the databases there were only very few 
polymorphisms recorded. I performed massive parallel sequencing of the whole exon regions of 
the WNK4 gene in the volunteers from both clinical studies but found only five polymorphisms 
which could be confirmed by other methods. Two novel non-synonymous polymorphisms in the 
kinase region of the WNK4 (S239W and V358A) were predicted to have deleterious effect on the 
protein function. 
 
4.1.1 Why different diuretic drugs? 
We analyzed different diuretic drugs in the two clinical studies for two reasons: First, to study 
the molecular genetic basis of inter-individual variation in pharmacokinetics of each drug. 
Second, to study the molecular genetic reasons behind variation in pharmacodynamics. 
Concerning the pharmacokinetic variation, the loop diuretic drugs and the thiazide were studied 





Concerning pharmacodynamics variation, the loop diuretic drugs were already studied in 
relation to polymorphisms in NKCC2, the thiazide in relation to NCC and triamterene was 
studied in relation to ENAC polymorphism. In this work, we focused on the regulation of the 
mentioned pharmacodynamics candidate genes. 
 
4.2 Phenotype-genotype analysis of the renal regulation candidate genes 
After having developed, performed and validated the genotyping of the 39 polymorphisms, we 
firstly performed an extensive exploratory screening to identify which of the promising 
polymorphisms may be associated with the tested renal functions before then focusing on the 
major possible finding. To study the association between the phenotypes and the 39 genotyped 
polymorphisms in Table 27, we had to take into account the multiple testing problem. Without 
adjusting for multiple testing, numerous significant associations were found (Table 28). On the 
other hand, many of these associations were not significant by adjusting for multiple testing at 
the appropriate calculated type-I-error margin (P<0.0001). At this level only the intronic SNP in 
the NR2C3 gene was significant, but in addition to the SNP-wise significance we took into 
account how consistent the associations with the other polymorphisms with p-values between 
0.01 and 0.0001 were. Consistent here means whether they appeared in both studies 
(independent unrelated volunteers) and with the same renal functions (e.g. K or Na excretion). 
For example, the five selected polymorphisms in the WNK1 gene were associated with 
differences in urine potassium, systolic blood pressure (SBP) and diastolic blood pressure (DBP) 
in the literature (Newhouse et al., 2009; Turner et al., 2005). In one of the studies, WNK1 
polymorphisms were also significantly associated with the relevant phenotypes after four weeks 
on hydrochlorothiazide (Turner et al., 2005). Nevertheless, in our studies the associations with 
WNK1 polymorphisms were only found in one of the clinical studies, and the associations were 
quantitatively weak and disappeared after adjusting for multiple testing (Table 28). In the 
aldosterone receptor gene, the associations were more consistent and the associations of one 






4.3 Aldosterone receptor polymorphisms 
Twelve polymorphisms in the aldosterone receptor were selected for genotyping. The selection 
was based on a literature review. Only polymorphisms in NR3C2 were selected which were 
known to have an association with specific biological or medical phenotypes. Surprisingly, an 
intronic polymorphism (rs3857080) had more effects than the well-studied non-synonymous 
polymorphism Ile180Val (rs5522). In this work, only known polymorphisms in the NR3C2 were 
genotyped for the volunteers from both clinical studies, but in a future perspective, it may be 
very promising to have a full exon sequence of this gene for the volunteers for two reasons: 
First, variation may be associated with several other more rare polymorphisms which may have 
escaped out of attention. Second, to check the linkage with the most prominent finding in my 
research, the intron 3 polymorphism, with all detected polymorphisms in the exon regions. The 
linkage to any polymorphism in the exon region may provide a more conclusive explanation why 
the polymorphism was associated with functional phenotypes. Only exon regions are suggested 
for sequencing because of the big gene size (almost 370 kb). 
 
4.3.1 Effects on ion excretion 
4.3.1.1 The intron 3 polymorphism (rs3857080) effects on in vivo salt and fluid homeostasis with 
and without diuretic drugs 
Sodium and chloride excretion after the loop diuretics bumetanide and furosemide, and 
potassium excretion under most circumstances were higher in carriers of the A-allele of the 
rs3857080 polymorphism. The difference was quantitatively significant and the aldosterone 
receptor polymorphism explained more variation (Figure 19) than other polymorphisms studied 
in this context (Vormfelde and Brockmoller, 2012). Torsemide was less affected by rs3857080 
than other loop diuretics but torsemide is also different from the others since it also has an 
antialdosteronergic effect (Uchida et al., 1991). However, data concerning the 
antialdosteronergic effects of torsemide to our knowledge only came from studies in rats 
(Uchida et al., 1991). 
High aldosterone receptor expression associated with the A-allele of rs3857080 may be derived 





under most conditions (Figure 17). Only after torsemide, which is a loop diuretic similar to 
bumetanide and furosemide which may additionally block the aldosterone receptor, potassium 
excretion was similar between the A- and the G-allele of rs3857080. One study showed that 
torsemide may inhibit the secretion of aldosterone (Goodfriend et al., 1998). The finding that an 
antialdosteronergic drug reduced or abolished the association of kaliuresis with the aldosterone 
receptor polymorphism may confirm our hypothesis that the polymorphism modulates 
aldosterone receptor expression and function.  
In this work, the urinary excretion under true steady state conditions was not measured. 
Nevertheless, in another study [Table S6 in (Tobin et al., 2008)], no association of 24 h urinary 
sodium, chloride and potassium excretion with rs3857080 was observed under steady state 
conditions. However, upon stimulation of aldosterone secretion by salt depletion and diuresis in 
this study, one can assume that participants had elevated aldosterone concentrations. Under 
this condition higher aldosterone receptor expression may be particularly functional resulting in 
higher aldosterone receptor function. 
rs3867080 appears to primarily affect the kaliuretic function of the aldosterone receptor (Figure 
17). While aldosterone is better known for sodium retention, it has two distinct functions; this 
has been termed the “aldosterone paradox” [1.5.2]. While sodium retention predominates in 
hypovolemia, kaliuresis predominates in normovolemia (Seva Pessoa et al., 2013), and in our 
studies, normovolemia was ensured by allowing the volunteers to drink as much water as they 
requested.  
4.3.1.2 Ile180Val polymorphism (rs5522) effects on in vivo salt and fluid homeostasis with and 
without diuretic drugs 
As a secondary finding of this research, Ile180Val (rs5522), which has earlier been studied by 
several authors (Derijk et al., 2008; Klok et al., 2011; Martinez et al., 2009; van Leeuwen et al., 
2011), may modulate the urinary excretion of electrolytes in some instances. This polymorphism 
is located in exon 2, coding the amino acid number 180 in the aldosterone receptor. The change 
from isoleucine to valine is in the N-terminal domain of the protein. This domain controls the 
transcriptional activity of the aldosterone receptor (MR) by recruiting a number of co-
regulators. It is suggested that this change may attenuate the activity of MR as the amino acid 





Comparatively high aldosterone receptor function may be associated with the valine allele of 
Ile180Val as observed in this work. High sodium&chloride excretion was associated with the 
valine allele after triamterene intake (Table 30, Figure 17). As triamterene blocks ENaC, a 
comparatively strong triamterene effect refers to high ENaC activity before the blocking. This 
suggests comparatively high aldosterone receptor function associated with the valine allele as 
the aldosterone receptor increases ENaC expression. 
Earlier findings about Ile180Val are inconclusive (Cavallari et al., 2010; DeRijk et al., 2006; 
Kortmann et al., 2013; Rovaris et al., 2013). At least, protection from hypertension has been 
related to a haplotype including the valine allele (Martinez et al., 2009). The large effect sizes 
potentially associated with Ile180Val, however worth its further investigation in kidney-related 
phenotypes. 
 
4.3.2 Functional characterization of the intron 3 polymorphism (rs3857080) 
As the primary finding of this research, the intronic aldosterone receptor polymorphism 
rs3857080 appeared to be a functional polymorphism with a considerable effect on the renal 
functions. There are several approaches to investigate an intronic polymorphism. First is to 
define any possible transcription factor binding site around this polymorphism. Second is to 
transfect the polymorphism region into selected cells and assess effects by the reporter gene 
assay. Third is to study the effect of the polymorphism on the gene expression in different 
tissues where the gene is highly expressed (e.g. the small intestine, colon, lungs, thyroid and 
kidneys) (Supplementary figure 5). Forth is to define any transcript variants splicing sites around 
the polymorphism region. The possibility of this polymorphism to be in a splicing region is low, 
although not excluded, because it is not close to any of the near exons, where the donor or 
receiver regions are usually located.  
4.3.2.1 Effects on protein binding – transcription factor binding site 
My in vitro experiments provided several types of evidence that the polymorphism is located at 
a LHX4 binding site (e.g. Figure 21) and that the transcription factor LHX4 binds with higher 
affinity to the minor A-allele than to the major G-allele (Figure 21). LHX4 is a member of the LIM 
homeodomain transcription factors known for its effects on pituitary gland differentiation and 





linked LHX4 to the aldosterone receptor expression or diuretic drugs’ efficacy; however, 
considering the impact of LHX4 on the pituitary gland which regulates cortisol biosynthesis may 
give some clues. Nevertheless, no final explanation on the molecular basis can be given other 
than its possible effect on transcription. 
4.3.2.2 Reporter gene assay 
4.3.2.2.1 Effects of rs3857080 region on the luciferase activity 
The activity of firefly luciferase was increased by about 1.7 fold compared to the control with 
the major-G and minor-A alleles of rs3857080. Surprisingly, this activity was not reduced or 
abolished when the mutated allele from the rs3857080 was transfected. The mutated allele of 
the rs3857080 showed completely no binding band with the EMSA experiments, and was 
expected to have no effect on the firefly luciferase alike the control. Another unexplained 
observation was that no clear difference in the luciferase activity between the major-G and 
minor-A alleles of rs3857080 was observed. It was expected then, that the co-transfection of 
the LHX4 factor with the major and minor alleles’ clones of rs3857080 would amplify the effect 
besides the difference. 
4.3.2.2.2 Effects of rs3857080 region on the luciferase activity when LHX4 is co-expressed 
The activity of firefly luciferase was clearly amplified when LHX4 was co-expressed compared to 
the last experiment without co-expressing the LHX4 (Figure 28). There was some increase in the 
activity of the luciferase when LHX4 was co-expressed even with the control. The increased 
activity in the control could be explained. The empty pGL3-promoter plasmid (the control) 
contained already possible binding sites for LHX4. The effect of the mutated allele of rs3857080 
on the luciferase was less than the major and minor allele but still not as low as the negative 
control. It is suggested to repeat the reporter gene assays with the same inserted regions but in 
different luciferase vectors. The vectors should be checked prior to exclude any possible binding 
site for the LHX4. 
4.3.3 Possible clinical consequences of the minor A-allele carriers of the intron 3 polymorphism 
(rs3857080) 
Clinically potentially relevant, the intron-3 polymorphism (rs3857080) affected electrolyte 





lead to hypokalemia and its devastating consequences. Clinically, one may speculate that 
carriers of the minor A-allele of rs3857080 are at higher risk of hypokalemia and consequently 
may have less favorable outcomes of diuretic therapy. The possibility to match this 
polymorphism with available antialdosteronergic drugs such as torsemide, spironolactone or 
eplerenone suggests the possibility of differential pharmacotherapy. Taken together, rs3857080 
appears interesting for future research in heart diseases, blood pressure and pharmacotherapy. 
Also antialdosteronergic drugs (e.g. spironolactone, eplerenone and torsemide) may be 
especially beneficial in A-allele carriers. 
 
4.4 WNK4 polymorphisms 
The WNK4 gene appears to be located in a non-polymorphic region of chromosome 17 (Table 
35). The last impression arises because genotyping the 19 exons of WNK4 in 229 healthy 
Caucasian men resulted only in 5 confirmed single nucleotide polymorphisms with a minor allele 
frequencies all around 1%. All detected and confirmed polymorphisms were heterozygous. 
 
Table 35: percentage of the polymorphisms through the studied genes 
Gene Nr. SNPs > 1% MAF * Nr. non-synonym SNPs > 1% MAF ** Gene size*** 
Ratio **** 
[per thousand bp] 
WNK1 555 5 158530 3.501 
WNK3 129 1 165183 0.781 
WNK4 20 1 16436 1.217 
STK39 921 4 293576 3.137 
OXSR1 188 1 89954 2.09 
SGK1 613 2 148813 4.119 
NEDD4L 1573 0 357154 4.404 
KCNJ1 102 0 29354 3.475 
CLCKA 78 9 12060 6.468 
CLCKB 145 7 13557 10.696 
NR3C2 1351 1 363758 3.714 
* The number of SNPs through the gene (Exon-intron) with minor allele frequency higher than 1%. The numbers were extracted 
from the 1000 genomes project. **The number of the non-synonymous SNPs in the European American population from the 
NHLBI Exome Sequencing Project (ESP) with minor allele frequency higher than 1%.  *** Genes’ sizes were calculated from the 







Two polymorphisms (S239 and V358A) were predicted to be deleterious by almost all tools used 
to evaluate the functional consequences from amino acid substitutions [See methods 2.10.3] (8 
and 9 deleterious out of 9 predictions respectively, Table 34). Both of the polymorphisms were 
found in the kinase region of the WNK4. The kinase region is a highly conserved region between 
the four WNKs, and they share about 84% sequence identity of this region (McCormick and 
Ellison, 2011). Figure 29 shows the relative positions of the polymorphisms in the WNK4 kinase 
with the number of deleterious predictions. Further in vitro experiments should follow to 
illustrate the actual role of these polymorphisms on the function and activity of the WNK4. A 
direct idea would be to study the kinase activity of the protein (Ahlstrom and Yu, 2009). In 
general, two approaches could be applicable: The first classical approach for such an experiment 
is to get a considerable purified amount of the kinase (WNK4) and to incubate it with 
radioactive ATP and a substrate (SPAK or OSR1), followed by kinase activity measurement. The 
second suggested approach is to measure the phosphorylated substrate of the kinase with a 
method like western blot. Both of the last mentioned approaches are not perfectly established 
yet and there could be a lot of difficulties and weak points in between. Difficulties and weak 
points could be: Getting the purified WNK4, getting a specific anti-phospho-substrate of the 
kinase and choosing the best specific activator of the WNK4 alone.  
 
 
  Figure 29: WNK4 detected polymorphisms 
Nr. D prediction is the number of deleterious predictions by the used tools for the corresponding polymorphism. The kinase 







Two aldosterone receptor polymorphisms, rs3857080 more strongly than Ile180Val, appeared 
to affect renal electrolyte handling under moderate salt restriction and diuretic intake. In 
particular, carriers of the A-allele of rs3857080 may be more prone to hypokalemia from 
diuretic therapy and its devastating consequences than carriers of the major G-allele. The A-
allele of rs3857080 may predict a sub-optimal outcome from diuretic therapy and heart 
diseases. Interestingly, the possible antialdosteronergic effect of torsemide may counteract 
genotype-dependent potassium excretion and torsemide may thus be indicated in carriers of 
the A-allele. One may hypothesize that spironolactone or eplerenone similarly attenuate or 
abolish the effect of rs3857080. Most of the work on NR3C2 was focused on its post-
translational role as transcription factor, but non as known have reported the effects on NR3C2 
gene pre-translational (Rogerson et al., 2004). In vitro results indicate that rs3857080 may affect 
the binding of the transcription factor LHX4 and may thus itself be a functional rather than a 
marker polymorphism. The effects of Ile180Val appeared less consistent. However, given the 
considerable effect sizes after triamterene, further research appears warranted. Hypertensive 
valine carriers may e.g. profit from triamterene more than expected. In conclusion, rs3857080, 
more than Ile180Val, is a new, highly promising candidate for further in vitro studies and clinical 
research. 
WNK4 is considered as disease gene, and seems to be not polymorphic. Genotyping all the 
exons for 229 healthy volunteers from two clinical studies revealed five polymorphisms. Two of 
these polymorphisms were novel and located in the kinase region. Both polymorphisms were 
predicted by the bioinformatics tools to have a deleterious effect on the protein function. In 
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6 Supplementary materials 
6.1.1 Genotyped polymorphisms, allele frequencies and Chi square calculations for Hardy-
Weinberg disequilibrium 
The total number of genotyped participants was 229. 110 were from the first clinical study, and 
119 from the second one. Calculations were done as the following: 
 
𝐴𝑙𝑙𝑒𝑙𝑒 𝑓𝑟𝑒𝑞𝑢𝑒𝑛𝑐𝑦 (𝐴𝐹) =
(2 × 𝑁𝑟. ℎ𝑜𝑚𝑜𝑧𝑦𝑔𝑜𝑢𝑠 𝑠𝑢𝑏𝑗𝑒𝑐𝑡𝑠) + 𝑁𝑟. ℎ𝑒𝑡𝑒𝑟𝑜𝑧𝑦𝑔𝑜𝑢𝑠 𝑠𝑢𝑏𝑗𝑒𝑐𝑡𝑠
2 × 𝑁𝑟. 𝑔𝑒𝑛𝑜𝑡𝑦𝑝𝑒𝑑 𝑠𝑢𝑏𝑗𝑒𝑐𝑡𝑠
 
Equation 1: Allele frequency (AF) 
 
𝐸𝑥𝑝𝑒𝑐𝑡𝑒𝑑 (𝐴 𝐴 𝑜𝑟 𝐵/𝐵) 𝑔𝑒𝑛𝑜𝑡𝑦𝑝𝑒𝑠 =⁄ 𝐴𝑙𝑙𝑒𝑙𝑒 𝑓𝑟𝑒𝑞𝑢𝑒𝑛𝑐𝑦 𝐴 (𝑜𝑟 𝐵)
× 𝐴𝑙𝑙𝑒𝑙𝑒 𝑓𝑟𝑒𝑞𝑢𝑒𝑛𝑐𝑦 𝐴 (𝑜𝑟 𝐵) × 𝑁𝑟. 𝑔𝑒𝑛𝑜𝑡𝑦𝑝𝑒𝑑 𝑠𝑢𝑏𝑗𝑒𝑐𝑡𝑠 
Equation 2: Expected (A)⁄A or B/B) genotypes 
 
𝐸𝑥𝑝𝑒𝑐𝑡𝑒𝑑 (𝐴 𝐵) 𝑔𝑒𝑛𝑜𝑡𝑦𝑝𝑒𝑠 =⁄ 𝐴𝑙𝑙𝑒𝑙𝑒 𝑓𝑟𝑒𝑞𝑢𝑒𝑛𝑐𝑦 𝐴 × 𝐴𝑙𝑙𝑒𝑙𝑒 𝑓𝑟𝑒𝑞𝑢𝑒𝑛𝑐𝑦 𝐵
× 𝑁𝑟. 𝑔𝑒𝑛𝑜𝑡𝑦𝑝𝑒𝑑 𝑠𝑢𝑏𝑗𝑒𝑐𝑡𝑠 
Equation 3:Expected (A/B) genotypes 
 
The numbers in the following tables in the observed and expected columns are referring to the 
number of genotyped people (not the number of alleles). 
6.1.1.1 Clinical study 1 (loop diuretics) 





Chi  Sqr 
A/A A/B B/B A/A A/B B/B A B 
CLCNKa_rs1010069_G/A 23 65 22 28 55 27 110 0.505 0.495 0.162 
KCNJ1_rs2846679_C/T 86 24 0 87 21 1 110 0.891 0.109 0.438 
KCNJ1_rs76640813_G/A NP NP NP NP NP NP NP NP NP NP 
KCNJ1_rs76937254_C/T NP NP NP NP NP NP NP NP NP NP 
NEDD4L_rs2288774_G/A 28 48 34 25 55 31 110 0.473 0.527 0.425 
NEDD4L_rs4149601_C/T 38 65 7 45 51 14 110 0.641 0.359 0.012 
NR3C2_rs1040288_G/C 38 57 15 40 53 17 110 0.605 0.395 0.680 
NR3C2_rs10519963_C/T 86 21 3 85 24 2 110 0.877 0.123 0.493 





NR3C2_rs11099681_C/T 52 52 6 55 45 9 110 0.709 0.291 0.310 
NR3C2_rs11737660_G/A 66 36 8 64 40 6 110 0.764 0.236 0.619 
NR3C2_rs2070951_G/C 28 56 26 29 55 27 110 0.509 0.491 0.981 
NR3C2_rs3846329_C/A 71 32 7 69 36 5 110 0.791 0.209 0.450 
NR3C2_rs3857080_G/A 87 22 1 87 21 1 110 0.891 0.109 0.955 
NR3C2_rs4835493_G/A 53 51 6 56 45 9 110 0.714 0.286 0.370 
NR3C2_rs5522_G/A 0 19 91 1 17 92 110 0.086 0.914 0.612 
NR3C2_rs5534_C/T 45 40 25 38 53 18 110 0.591 0.409 0.034 
NR3C2_rs6810951_C/A 37 59 14 40 53 17 110 0.605 0.395 0.442 
OXSR1_rs113919536_C/A NP NP NP NP NP NP NP NP NP NP 
OXSR1_rs35295772_A/T NP NP NP NP NP NP NP NP NP NP 
OXSR1_rs457661_G/A NP NP NP NP NP NP NP NP NP NP 
OXSR1_rs6599079_G/A 86 23 1 86 22 1 110 0.886 0.114 0.924 
SGK1_rs1057293_C/T 83 27 0 85 24 2 110 0.877 0.123 0.341 
SGK1_rs9493857_C/T 74 31 5 73 33 4 110 0.814 0.186 0.760 
WNK1_rs1159744_G/C 8 44 58 8 44 58 110 0.273 0.727 0.996 
WNK1_rs2107614_G/A 47 51 12 48 49 13 110 0.659 0.341 0.946 
WNK1_rs2277869_C/T 5 28 77 3 31 75 110 0.173 0.827 0.518 
WNK1_rs3088353_G/T 25 49 36 22 54 33 110 0.450 0.550 0.576 
WNK1_rs765250_G/A 13 50 47 13 50 47 110 0.345 0.655 0.999 
FAM120C_rs2495801_C/T 97 chr X 13 chr X chr X chr X 110 0.882 0.118 chr X 
WNK3_rs3021280_G/T 107 chr X 3 chr X chr X chr X 110 0.973 0.027 chr X 
WNK3_rs3021284_A/T 100 chr X 10 chr X chr X chr X 110 0.909 0.091 chr X 
WNK3_rs3021285_C/T 100 chr X 10 chr X chr X chr X 110 0.909 0.091 chr X 
WNK3_rs7880501_C/T 107 chr X 3 chr X chr X chr X 110 0.973 0.027 chr X 
WNK4_rs61755606_G/A 91 18 1 91 18 1 110 0.909 0.091 0.995 
WNK4_rs75596106_G/C NP NP NP NP NP NP NP NP NP NP 
WNK4_rs77012584_C/T NP NP NP NP NP NP NP NP NP NP 
WNK4_rs77879367_G/T NP NP NP NP NP NP NP NP NP NP 
WNK4_rs78645838_G/A 99 11 0 99 10 0 110 0.950 0.050 0.859 
NP not polymorphic 
6.1.1.2 Clinical study 2 (Thiazide and Triamterene) 
Supplementary table 2: Genotyped polymorphisms, allele frequencies and Chi square for the second clinical study 
Polymorphism Observed Expected 
Total 
Allele Frequency Chi  Sqr 
 
A/A A/B B/B A/A A/B B/B A B 
 
CLCNKa_rs1010069_G/A 36 60 23 37 59 24 119 0.555 0.445 0.975 
KCNJ1_rs2846679_C/T 83 32 4 82 33 3 119 0.832 0.168 0.916 
KCNJ1_rs76640813_G/A NP NP NP NP NP NP NP NP NP NP 
KCNJ1_rs76937254_C/T NP NP NP NP NP NP NP NP NP NP 
NEDD4L_rs2288774_G/A 25 60 34 25 59 34 119 0.462 0.538 0.988 





NR3C2_rs1040288_G/C 37 56 26 36 59 25 119 0.55 0.45 0.858 
NR3C2_rs10519963_C/T 89 25 5 87 30 3 119 0.85 0.15 0.208 
NR3C2_rs11099680_C/T 63 44 12 61 49 10 119 0.71 0.29 0.590 
NR3C2_rs11099681_C/T 62 45 12 60 49 10 119 0.71 0.29 0.673 
NR3C2_rs11737660_G/A 72 38 9 70 43 7 119 0.76 0.24 0.470 
NR3C2_rs2070951_G/C 33 57 29 32 59 28 119 0.517 0.483 0.905 
NR3C2_rs3846329_C/A 73 39 7 72 41 6 119 0.78 0.22 0.844 
NR3C2_rs3857080_G/A 93 25 1 94 24 2 119 0.887 0.113 0.889 
NR3C2_rs4835493_G/A 63 44 12 61 49 10 119 0.71 0.29 0.590 
NR3C2_rs5522_G/A 1 24 94 1 23 94 119 0.109 0.891 0.925 
NR3C2_rs5534_C/T 43 54 22 41 58 20 119 0.59 0.41 0.788 
NR3C2_rs6810951_C/A 43 61 15 45 56 17 119 0.62 0.38 0.649 
OXSR1_rs113919536_C/A NP NP NP NP NP NP NP NP NP NP 
OXSR1_rs35295772_A/T NP NP NP NP NP NP NP NP NP NP 
OXSR1_rs457661_G/A NP NP NP NP NP NP NP NP NP NP 
OXSR1_rs6599079_G/A 98 19 2 97 21 1 119 0.903 0.097 0.647 
SGK1_rs1057293_C/T 92 25 2 92 25 2 119 0.878 0.122 0.980 
SGK1_rs9493857_C/T 74 43 2 77 38 5 119 0.803 0.197 0.311 
WNK1_rs1159744_G/C 2 45 72 5 39 75 119 0.206 0.794 0.233 
WNK1_rs2107614_G/A 65 50 4 68 44 7 119 0.756 0.244 0.312 
WNK1_rs2277869_C/T 7 32 80 4 37 77 119 0.193 0.807 0.324 
WNK1_rs3088353_G/T 36 46 37 29 59 30 119 0.496 0.504 0.047 
WNK1_rs765250_G/A 4 51 64 7 44 67 119 0.248 0.752 0.265 
FAM120C_rs2495801_C/T 107 chr X 12 chr X chr X chr X 119 0.899 0.101 chr X 
WNK3_rs3021280_G/T 117 chr X 2 chr X chr X chr X 119 0.983 0.017 chr X 
WNK3_rs3021284_A/T 108 chr X 11 chr X chr X chr X 119 0.908 0.092 chr X 
WNK3_rs3021285_C/T 108 chr X 11 chr X chr X chr X 119 0.908 0.092 chr X 
WNK3_rs7880501_C/T 117 chr X 2 chr X chr X chr X 119 0.983 0.017 chr X 
WNK4_rs61755606_G/A 102 16 1 102 17 1 119 0.924 0.076 0.916 
WNK4_rs75596106_G/C NP NP NP NP NP NP NP NP NP NP 
WNK4_rs77012584_C/T NP NP NP NP NP NP NP NP NP NP 
WNK4_rs77879367_G/T NP NP NP NP NP NP NP NP NP NP 
WNK4_rs78645838_G/A 109 9 1 108 10 0 119 0.954 0.046 0.300 
NP not polymorphic 
6.1.1.3 Both clinical studies 
Supplementary table 3: Genotyped polymorphisms, allele frequencies and Chi square for the both clinical studies 
Polymorphism Observed Expected 
Total 
Allele Frequency Chi  Sqr 
 
A/A A/B B/B A/A A/B B/B A B 
 
CLCNKa_rs1010069_G/A 59 125 45 64 114 50 229 0.531 0.469 0.350 
KCNJ1_rs2846679_C/T 169 56 4 169 55 4 229 0.860 0.140 0.967 





KCNJ1_rs76937254_C/T NP NP NP NP NP NP NP NP NP NP 
NEDD4L_rs2288774_G/A 68 108 53 65 114 50 229 0.533 0.467 0.728 
NEDD4L_rs4149601_C/T 95 115 19 102 102 26 229 0.666 0.334 0.150 
NR3C2_rs1040288_G/C 75 113 41 76 112 42 229 0.574 0.426 0.990 
NR3C2_rs10519963_C/T 175 46 8 171 54 4 229 0.865 0.135 0.100 
NR3C2_rs11099680_C/T 115 96 18 116 94 19 229 0.712 0.288 0.947 
NR3C2_rs11099681_C/T 114 97 18 115 94 19 229 0.710 0.290 0.915 
NR3C2_rs11737660_G/A 138 74 17 134 83 13 229 0.764 0.236 0.294 
NR3C2_rs2070951_G/C 61 113 55 60 114 54 229 0.513 0.487 0.982 
NR3C2_rs3846329_C/A 144 71 14 141 78 11 229 0.784 0.216 0.437 
NR3C2_rs3857080_G/A 180 47 2 181 45 3 229 0.889 0.111 0.855 
NR3C2_rs4835493_G/A 116 95 18 117 94 19 229 0.714 0.286 0.972 
NR3C2_rs5522_G/A 185 43 1 186 41 2 229 0.902 0.098 0.665 
NR3C2_rs5534_C/T 88 94 47 80 111 39 229 0.590 0.410 0.071 
NR3C2_rs6810951_C/A 80 120 29 86 109 35 229 0.611 0.389 0.299 
OXSR1_rs113919536_C/A NP NP NP NP NP NP NP NP NP NP 
OXSR1_rs35295772_A/T NP NP NP NP NP NP NP NP NP NP 
OXSR1_rs457661_G/A NP NP NP NP NP NP NP NP NP NP 
OXSR1_rs6599079_G/A 184 42 3 184 43 3 229 0.895 0.105 0.943 
SGK1_rs1057293_C/T 175 52 2 176 49 3 229 0.878 0.122 0.681 
SGK1_rs9493857_C/T 148 74 7 149 71 8 229 0.808 0.192 0.826 
WNK1_rs1159744_G/C 130 89 10 133 83 13 229 0.762 0.238 0.557 
WNK1_rs2107614_G/A 112 101 16 115 94 19 229 0.710 0.290 0.569 
WNK1_rs2277869_C/T 157 60 12 153 69 8 229 0.817 0.183 0.166 
WNK1_rs3088353_G/T 73 95 61 63 114 51 229 0.526 0.474 0.039 
WNK1_rs765250_G/A 111 101 17 114 95 20 229 0.705 0.295 0.655 
FAM120C_rs2495801_C/T 204 chr X 25 chr X chr X chr X 229 0.891 0.109 chr X 
WNK3_rs3021280_G/T 224 chr X 5 chr X chr X chr X 229 0.978 0.022 chr X 
WNK3_rs3021284_A/T 208 chr X 21 chr X chr X chr X 229 0.908 0.092 chr X 
WNK3_rs3021285_C/T 208 chr X 21 chr X chr X chr X 229 0.908 0.092 chr X 
WNK3_rs7880501_C/T 224 chr X 5 chr X chr X chr X 229 0.978 0.022 chr X 
WNK4_rs61755606_G/A 193 34 2 193 35 2 229 0.917 0.083 0.935 
WNK4_rs75596106_G/C NP NP NP NP NP NP NP NP NP NP 
WNK4_rs77012584_C/T NP NP NP NP NP NP NP NP NP NP 
WNK4_rs77879367_G/T NP NP NP NP NP NP NP NP NP NP 
WNK4_rs78645838_G/A 208 20 1 208 21 1 229 0.952 0.048 0.793 







6.1.2 Effects of the twelve selected polymorphisms in NR3C2 gene on NaCl and K+ excretion 
between 0 and 24 h 
To calculate the mean effect of the minor allele for each SNP, new compliment variable for each 
SNP was coded using SPSS® v20.0. The univariate command in SPSS® was used on both variables 
(SNP and its complimentary) using the main effect model and the “estimate parameters” 
option. The effects of one minor allele was calculated, after that the effect of one minor allele 
was multiplied by 2 to mimic the 2 minor allele effects. 
The impact of 12 SNPs on potassium excretion after administration of bumetanide and 
torsemide. The figure depicts the difference in K+ excretion between the participants carrying 
two minor alleles from each SNP. Each rhombus reflects the mean amount of K+ excreted in 24h 
and the area of it reflects the number on the minor allele carriers in our clinical studies. Figures 






6.1.2.1 After moderate sodium chloride restriction 
 
 
Supplementary figure 1: The impact of 12 SNPs on sodium chloride and potassium excretion after moderate sodium chloride 
restriction 
The figure depicts the difference in NaCl and K+ excretion between the participants carrying 2 minor alleles for each SNP. Each 
rhombus reflects the mean amount of K+ excreted in 24 h and the area of it reflects the number on the minor allele carriers in our 






6.1.2.2 After bumetanide, furosemide and torsemide 
 
 
Supplementary figure 2: The impact of 12 SNPs on sodium chloride and potassium excretion after bumetanide, furosemide and 
torsemide 
The figure depicts the difference in NaCl and K+ excretion between the participants carrying 2 minor alleles for each SNP. Each 
rhombus reflects the mean amount of K+ excreted in 24 h and the area of it reflects the number on the minor allele carriers in our 






6.1.2.3 After hydrochlorothiazide 
 
 
Supplementary figure 3: The impact of 12 SNPs on sodium chloride and potassium excretion after hydrochlorothiazide 25 and 
100 mg 
The figure depicts the difference in NaCl and K+ excretion between the participants carrying 2 minor alleles for each SNP. Each 
rhombus reflects the mean amount of K+ excreted in 24 h and the area of it reflects the number on the minor allele carriers in our 






6.1.2.4 After triamterene 
 
 
Supplementary figure 4: The impact of 12 SNPs on sodium chloride and potassium excretion after triamterene 
The figure depicts the difference in NaCl and K+ excretion between the participants carrying 2 minor alleles for each SNP. Each 
rhombus reflects the mean amount of K+ excreted in 24 h and the area of it reflects the number on the minor allele carriers in our 






6.1.3 Predicted transcription factors by TRANSFAC® 
The next table is summarizing the different transcription factors binding sites behavior (TFBS) of 
the transcription factors that have a known Position Weight Matrix (PWM) in TRANSFAC. The 
last two columns in the table are describing the frequencies for which these used PWM was 
found in the major-G allele of rs3857080 (WT) sequence or in the minor-A allele of rs3857080 
(variant). When 0 appears in the WT frequency column, it means no hit for that PWM in WT but 
a hit in the variant sequence. Some hits are found only or more frequently in the WT-sequence 
compared to the variant. This explains the different number in non-zero entries. 
 















V$MSX1_02 Msx-1 14 15 V$PITX3_01 Pitx3 2 1 
V$SOX4_01 Sox4 13 15 V$TCF1_07 Tcf1 2 1 
V$NKX12_01 Nkx1-2 13 12 V$CDP_02 CDP 2 0 
V$BARX1_01 Barx1 10 11 V$SOX5_04 Sox5 2 0 
V$LHX4_01 Lhx4 10 11 V$HMGIY_01 HMGIY 1 3 
V$NKX11_01 Nkx1-1 10 9 V$OCT1_07 Oct-1 1 3 
V$RAX_01 rax 10 9 V$PAX6_01 Pax-6 1 3 
V$TBX5_Q5 TBX5 9 11 V$SRY_02 SRY 1 3 
V$E2F1_01 E2F-1 9 8 V$AP1_01 AP-1 1 2 
V$GBX2_01 Gbx2 8 10 V$AP1_02 AP1 1 2 
V$HOXC6_01 HOXC6 8 7 V$AP1_Q6_02 AP-1 1 2 
V$NKX24_01 Nkx2-4 7 8 V$CDX2_Q5 Cdx-2 1 2 
V$PMX2A_01 PMX2A 7 8 V$CREBP1CJUN_01 ATF2:c-Jun 1 2 
V$ALX3_01 Alx3 6 8 V$ELF4_04 Elf3 1 2 
V$BARHL1_01 Barhl-1 6 8 V$FOXD3_01 FOXD3 1 2 
V$HOXA10_01 HOXA10 6 8 V$FXR_Q3 FXR/RXR-alpha 1 2 
V$HOXD10_01 HOXD10 6 8 V$HOXA9_01 hoxa9 1 2 
V$ISGF4G_04 Isgf3g 6 8 V$IPF1_05 IPF1 1 2 
V$NKX26_01 Nkx2-6 6 8 V$MAFB_01 MAFB 1 2 
V$ESX1_01 Esx1 6 7 V$OCT1_Q6 Oct-1 1 2 
V$HMX3_02 Nkx5-1 6 7 V$OCTAMER_02 Octamer 1 2 
V$HOXA3_02 HOXA3 6 7 V$PAX8_01 Pax-8 1 2 
V$HOXC4_01 HOXC4 6 7 V$PBX1_04 Pbx1 1 2 
V$ISL2_01 Isl2 6 7 V$PBX1_05 Pbx 1 2 
V$LMX1_01 Lmx-1 6 7 V$SOX1_03 Sox1 1 2 
V$LMX1B_01 lmx1b 6 7 V$SOX7_04 Sox7 1 2 
V$NKX52_01 Nkx5-2 6 7 V$SOX8_04 Sox8 1 2 
V$PMX2B_01 PMX2B 6 7 V$SOX9_B1 SOX9 1 2 
V$UNCX4.1_01 Uncx-4.1 6 7 V$XFD1_01 XFD-1 1 2 
V$SRF_06 Srf 6 5 V$XFD2_01 XFD-2 1 2 
V$BRN4_01 Brn-4 5 7 V$ZIC2_05 Zic2 1 2 





V$K2B_01 K-2b 5 7 V$CACD_01 CACD 1 0 
V$BARHL2_01 Barhl2 5 6 V$CDPCR3HD_01 CDP CR3+HD 1 0 
V$LHX61_01 lhx6.1 5 6 V$CLOX_01 Clox 1 0 
V$LHX8_01 Lhx8 5 6 V$CMAF_01 c-Maf 1 0 
V$PROP1_02 Prop-1 5 6 V$CREBATF_Q6 CREB, ATF 1 0 
V$CDP_04 CDP 5 4 V$GATA1_01 GATA-1 1 0 
V$HOXA2_01 HoxA2 5 4 V$GATA2_03 GATA-2 1 0 
V$HOXA6_01 HOXA6 5 4 V$GATA3_03 GATA-3 1 0 
V$HOXD11_01 HOXD11 5 4 V$GATA6_05 Gata-6 1 0 
V$SRY_01 SRY 5 4 V$GFI1B_01 Gfi1b 1 0 
V$VAX1_01 Vax-1 5 4 V$GMEB1_04 Gmeb1 1 0 
V$EN1_02 En-1 4 6 V$IRF5_03 IRF-5 1 0 
V$EVX1_01 Evx-1 4 6 V$IRF6_03 IRF-6 1 0 
V$HDX_01 Hdx 4 6 V$IRF7_01 IRF-7 1 0 
V$HMGIY_Q3 HMGIY 4 6 V$ISGF3G_03 IRF-9 1 0 




V$MSX3_01 Msx-3 4 6 V$MUSCLEINI_B Muscle initiator 1 0 
V$NKX63_01 Nkx6-3 4 6 V$NRF2_Q4 Nrf-2 1 0 
V$TST1_02 Oct-6 4 6 V$OTX_Q1 OTX 1 0 
V$EMX2_01 EMX2 4 5 V$PAX5_02 Pax-5 1 0 




4 5 V$SMAD_Q6 SMAD 1 0 
V$HOXA1_01 HOXA1 4 5 V$SP100_04 Sp100 1 0 
V$HOXB6_01 HOXB6 4 5 V$AP1_Q2 AP-1 0 2 
V$HOXB7_01 HOXB7 4 5 V$ARID5A_03 Arid5a 0 2 
V$MEIS2_01 Meis2 4 5 V$BRN2_01 Brn-2 0 2 
V$NKX25_02 Nkx2-5 4 5 V$CART1_02 CART1 0 2 
V$OTP_01 OTP 4 5 V$CEBPG_Q6 C/EBPgamma 0 2 
V$RHOX11_01 Rhox11 4 3 V$OG2_02 OG-2 0 2 
V$RHOX11_02 Rhox11 4 3 V$PAX4_05 Pax-4 0 2 
V$SIX3_01 Six-3 4 3 V$SOX11_04 Sox11 0 2 
V$SIX6_02 Six-6 4 3 V$SOX5_07 Sox4 0 2 
V$SIX1_01 Six-1 4 2 V$AHR_01 AhR 0 1 
V$HOXB9_01 HOXB9 3 5 V$AP1FJ_Q2 AP-1 0 1 
V$HOXC9_01 HOXC9 3 5 V$AP1_Q2_01 AP-1 0 1 
V$MSX2_01 Msx-2 3 5 V$AP1_Q4 AP-1 0 1 
V$PAX6_02 pax6 3 5 V$AP1_Q4_01 AP-1 0 1 
V$SOX15_04 Sox15 3 5 V$AP1_Q6 AP-1 0 1 
V$CAP_01 cap 3 4 V$AP1_Q6_01 AP-1 0 1 
V$GEN_INI2_B GEN_INI 3 4 V$CFOS_Q6 c-Fos 0 1 
V$GEN_INI3_B GEN_INI 3 4 V$CJUN_Q6 C-Jun 0 1 
V$GEN_INI_B GEN_INI 3 4 V$CREB1_Q6 CREB1 0 1 
V$HOXA4_Q2 HOXA4 3 4 V$CREB_Q3 CREB 0 1 
V$HOXD13_01 HOXD13 3 4 V$DMRT4_01 DMRT4 0 1 
V$LEF1_03 Lef1 3 4 V$ERALPHA_Q6_01 ER-alpha 0 1 
V$NKX25_03 NKX25 3 4 V$ERALPHA_Q6_02 ER-alpha 0 1 
V$SOX17_04 Sox17 3 4 V$ER_Q6 ER 0 1 
V$SOX5_01 SOX5 3 4 V$ESR1_01 ESR1 0 1 
V$SRY_Q6 SRY 3 4 V$FOXA2_04 HNF3-beta 0 1 





V$HNF4A_02 Hnf4a 3 2 V$HMEF2_Q6 MEF-2 0 1 
V$OBOX3_01 Obox3 3 2 V$HNF1_Q6 HNF1 0 1 
V$OTX3_01 Otx3 3 2 V$HNF4A_04 HNF4-alpha 0 1 
V$SIX4_01 six4 3 2 V$HNF6_Q4 HNF-6 0 1 
V$SIX6_01 Six-6 3 2 V$ICSBP_Q6 ICSBP 0 1 
V$CPHX_01 Cphx 3 1 V$JUNB_Q6 JunB 0 1 
V$GATA1_03 GATA-1 3 1 V$JUND_Q6 JunD 0 1 
V$OBOX2_01 Obox2 3 1 V$LXR_Q6 LXR; FXR 0 1 
V$OBOX5_02 Obox5 3 1 V$MAFK_04 Mafk 0 1 
V$TST1_01 Tst-1 2 6 V$MAF_Q6_01 MAF 0 1 
V$CART1_03 CART1 2 4 V$MEF2_01 MEF-2 0 1 
V$DLX5_Q3 dlx5 2 4 V$MEF2C_Q4 MEF-2C 0 1 
V$EVX2_01 Evx2 2 4 V$MEIS1_01 MEIS1 0 1 
V$HB9_01 HB9 2 4 V$MEIS1AHOXA9_01 MEIS1A:HOXA9 0 1 
V$HOX13_02 HOXA5 2 4 V$MYOGNF1_01 myogenin / NF-1 0 1 
V$OCT1_08 Oct-1 2 4 V$NKX25_Q5 Nkx2-5 0 1 
V$POU4F1_Q6 POU4F1 2 4 V$OC2_Q3 OC-2 0 1 
V$PSX1_01 PSX1 2 4 V$PAX4_01 Pax-4 0 1 
V$BRN1_Q6 BRN1 2 3 V$PAX_Q6 Pax 0 1 
V$BRN3C_01 Brn-3c 2 3 V$PBX1_02 Pbx-1b 0 1 
V$CMAF_02 C-MAF 2 3 V$PBX1_03 Pbx-1 0 1 
V$FOXA2_02 Foxa2 2 3 V$PLZF_02 PLZF 0 1 
V$FOXM1_01 FOXM1 2 3 V$PPARG_01 PPARgamma:RXRalpha 0 1 




V$NCX_01 Ncx 2 3 V$RARA_04 Rara 0 1 
V$NCX_02 Ncx 2 3 V$RBPJK_01 RBP-Jkappa 0 1 
V$NFE2_01 NF-E2 2 3 V$SOX15_03 Sox15 0 1 
V$NKX25_01 Nkx2-5 2 3 V$SOX18_03 Sox18 0 1 
V$NKX25_Q6 Nkx-2.5 2 3 V$TBR2_01 TBR2 0 1 
V$PAX4_02 Pax-4 2 3 V$TCF11_01 TCF11 0 1 
V$PIT1_01 Pit-1 2 3 V$TCF7L2_04 Tcf7l2 0 1 
V$PRX2_Q2 Prx2 2 3 V$TITF1_Q3 TTF1 (Nkx2-1) 0 1 
V$SRY_05 Sry 2 3 V$XFD3_01 XFD-3 0 1 
V$FOXO1_04 FOXO1 2 1 V$YB1_Q4 YB-1 0 1 
V$IRF4_04 Irf4 2 1 V$YY1_01 YY1 0 1 
V$MSX2_Q3 Msx-2 2 1 V$ZFP105_04 Zfp105 0 1 







6.1.4 Validating WNK4 polymorphisms 
The 5 detected and validated SNPs were genotyped in two batches among the 25th possible 
detected polymorphisms. The used primers for making the PCR and SNaPShot® reactions are 
listed in the following tables: 
 
Supplementary table 5: PCR primers for validating 5 SNPs in the WNK4 gene 
Primer name Sequence Amplicon lenght Batch 
V358A_F GGCCAGAGTGCCCAGCAATCTGATC 218 1 
V358A_r GCCCCATCCCTCTCACCGAAGTGAC 218 1 
S239W_f TGGGTGTCCTGGGCCTGACATGACA 213 1 
S239W_r TGAGCGTGCCCGAGGTCATGAGTTC 213 1 
P1025L_f GCTGGCGCCCATCTCTGAAGGTAAG 289 1 
P1025L_r CCGCCTCCAGCACTGTCCTCTGTAT 289 1 
R1204C_f 
CCGTGCATCCTCAGGCACTTGTCAG 412 2 
R1204C_r CCGGTGCTGCTGCCACTCAGAGAGT 412 2 
S1073G_V1084A_f TTGGGCGTTTCCAAGTGACTTCATC 373 2 
S1073G_V1084A_r AGCTCAGCCCAGAACTCCTCATCTT 373 2 
 
Supplementary table 6: SNaPShot primers for validating 5 SNPs in the WNK4 gene 
Primer Sequence Allele 1 Allele 2 Primer Length Batch 
V358A TGCACATGCCGAACGCGTAC A G 20 1 
S239W gatcgatcCATCGTCCGCTTCTATGATT C G 28 1 
P1025L_2 gatcgatcgatcgatcgatcTCCAAGTGACTTCATCCAAGGAAC C T 44 1 
V1084A gatcgatcTGAGGGTCTGGGGGCTGGAG T C 28 2 







6.1.5 Gene expression in 20 tissues panel (NR3C2 – WNK4) 
Complimentary DNA was synthesized from mRNA of 20 tissues panel [methods 6.10]. Quantitative PCR 
was performed for both genes NR3C2 (the aldosterone receptor) and WNK4 (With no Lysine kinase 4) 
with the house keeping gene TBP (TATA box binding protein). Comparing the expression of both genes 
showed that WNK4 is expressed more than the NR3C2 in some tissues while NR3C2 is widely expressed 
over the different tissues. 
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